Document:

Exclusive Development, Distribution and Supply Agreement

 Exhibit 10.21 
 CONFIDENTIAL TREATMENT 
 EXCLUSIVE DEVELOPMENT, DISTRIBUTION, AND SUPPLY AGREEMENT 

This EXCLUSIVE DEVELOPMENT, DISTRIBUTION, AND SUPPLY AGREEMENT (the
“Agreement”) is entered into as of October 27th, 2006 (the “Effective Date”), by and between
(i) CryoLife, Inc., a Florida corporation, having a principal place of business at 1655 Roberts Blvd. NW, Kennesaw, Georgia 30144 (“Supplier”), and (ii) BioForm Medical, Inc., a Delaware corporation having a
principal place of business at 1875 South Grant Street, Suite 110, San Mateo, California 94402 (“BioForm”). 
 Background 
 WHEREAS, Supplier has developed and manufactures products based on serum albumin technology for use as a
surgical adhesive product. 
 WHEREAS, BioForm desires to develop, market, distribute, and sell adhesive products in the Territory (as
defined herein) for use in the Field as exclusive distributor for the Term (as defined herein); and 
 WHEREAS, Supplier desires to
appoint BioForm as exclusive distributor of Company Product in the Territory for use in the Field. 
 NOW, THEREFORE, in consideration
of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each of the parties, Supplier and BioForm agree as follows: 
 1. DEFINITIONS 
 Capitalized terms used in this
Agreement and not otherwise defined herein shall have the respective meanings set forth below. 
 “Act” means the
United States Food, Drug and Cosmetic Act and similar laws and regulations in foreign jurisdictions within the Territory that regulate the manufacture, distribution, and sale of Company Product, all as may be amended from time to time. 

“Affiliate” means, with respect to any person, any person that, directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with, such person. For the purposes of this definition, “control” means the direct or indirect ownership of more than 50 percent of the outstanding shares or other voting rights
entitled to vote for the election of directors (or in the case of an entity that is not a corporation, for the election of the corresponding management authority). Supplier shall not be deemed for any purposes of this Agreement to be an Affiliate of
BioForm. 
 “BioForm Trademarks” means all trademarks, other marks, and trade dress used by BioForm to identify
Company Product, any other product or service of BioForm, or the business identity of BioForm. 
 “BioGlue Surgical Adhesive” means Supplier’s BioGlue® surgical adhesive product described in the BSA Specifications and
that consists of a surgical adhesive composed of purified bovine serum albumin and glutaraldehyde. 
 “BSA Patents”
means (a) the Patent Rights identified on Exhibit A; (b) all non-provisionals, divisions, substitutions, continuations, and continuations-in-part applications of any of the Patent Rights identified on Exhibit A; (c) all patents
that may issue from any of the Patent Rights identified on Exhibit A; (d) any reissues and reexaminations of the Patent Rights identified on Exhibit A; and (e) all foreign and international counterparts of the Patent Rights identified on
Exhibit A. 
  

 “BSA Specifications” means the specifications for the BioGlue Surgical Adhesive
set forth on Exhibit B, as such specifications may be amended from time to time in accordance with the terms of this Agreement. 
 “Bulk Product Sample” means a unit of non-sterile Company Product provided unpouched in bulk quantities. 
 “Business Day” (whether such phrase is capitalized or not) means any day, other than Saturday, Sunday, or a legal holiday in California, that banks located in San Francisco, California are open
for business. 
 “Company Product” means a single syringe with 2 milliliters of deliverable volume (approximately 3
milliliters of fill volume) of BioGlue Surgical Adhesive with up to four applicator or spreader tips in a sterile pouch packaged in private label form specific to BioForm in a box provided by BioForm, which box may vary depending on the country to
which the Company Product will be shipped or other circumstances. Company Product includes Improvements that BioForm elects, with Supplier’s concurrence, to incorporate into Company Products pursuant to Section 8.4(a). 
 “Confidential Information” means all data, specifications, training materials, and other know-how related to the design, use,
implementation, performance, manufacture, distribution, or sale of BioGlue Surgical Adhesive or any Company Product, as well as all other information and data provided by either party to the other party hereunder in written or other tangible medium
and marked as confidential, or if disclosed orally or displayed, identified as confidential prior to or at the time of disclosure and confirmed in writing as confidential within 30 calendar days after disclosure, in each case except any portion
thereof that: (a) is rightfully known to the receiving party before receipt thereof under this Agreement as evidenced by the receiving party’s written records; (b) is properly and lawfully disclosed to the receiving party by a third
person who has the legal right to make such disclosure; (c) is or becomes generally lawfully known in the trade through no fault of the receiving party; or (d) is independently developed by the receiving party without use of such
information, as evidenced by the receiving party’s written records. 
 “Field” means sales to plastic surgeons,
facial plastic surgeons, ear, nose, and throat surgeons, occuloplastic surgeons and dermatologists for use in the following cosmetic and reconstructive procedures of the face, neck, and breast: (a) full-face lifts, mid-face lifts, brow lifts,
neck lifts, and other facial cosmetic facial reconstructive procedures; and (b) lifts, reductions, reconstructions, and augmentations of the breast. The Field may be expanded to include specific non-facial, non-breast surgical procedures
performed by plastic surgeons, facial plastic surgeons, ear, nose, and throat surgeons, occuloplastic surgeons, and dermatologists with the written consent of both parties. “FDA” means the United States Food and Drug
Administration, or any successor entity. 
 “Improvements” means developments, Enhancements, updates, and
other changes the Company Product or any component of the Company Product. 
 “Intellectual Property”
means intellectual property or proprietary rights of any description including: United States and foreign Patent Rights, trademarks, service marks, and registrations thereof and applications therefor, copyrights and copyright registrations and
applications, mask works and registrations thereof, know-how, trade secrets, inventions, discoveries, ideas, technology, data, information, processes, drawings, designs, licenses, computer programs and software, and technical information (including
information embodied in material specifications, processing instructions, equipment specifications, product specifications, confidential data, electronic files, research notebooks, invention disclosures, research and development reports and the like
related thereto), and all amendments, modifications, and improvements to any of the foregoing. 
  

 – 2 – 

 “Patent Rights” means all patents, patent applications (including
any provisionals, continuations, divisionals, continuations-in-part, extensions, renewals, reissues, revivals, and reexaminations, any national phase PCT applications, any PCT international applications, and all foreign counterparts) and rights to
file patent applications, any reissues or extensions thereof and any foreign counterparts, divisions, continuations, or continuation-in-part of any applications or substitutes therefor. 
 “Product Approvals” means, for any country or other jurisdiction in the Territory, those regulatory approvals required for
importation, exportation, promotion, pricing, marketing, and sale of the Company Product in such country or other jurisdiction for use in the Field. 
 “Product Specifications” means the specifications for the Company Product as they are agreed to in writing from time to time in accordance with the terms of this Agreement.

 “Proprietary Rights” means Intellectual Property licensed to, owned or controlled by Supplier that
is used in the design, formulation, manufacturing or packaging of the Company Product. 
 “Regulatory Authority”
means the FDA and any other national, supra-national, regional, state, or local regulatory agency, department, bureau, commission, council, or other governmental entity empowered by any Act to regulate the Company Product (including the manufacture,
distribution, or sale of the Company Product) within the Territory. 
 “SA Product” means any surgical adhesive
capable of being used in the Field that is composed of serum albumin combined with any aldehyde or whose design or formulation is covered by any claim of the BSA Patents. 
 “Supplier Trademarks” means the BioGlue trademark and all other marks and trade dress used by Supplier to identify the BioGlue Surgical Adhesive or the business identity of
Supplier. Supplier Trademarks include, without limitation, those marks and trade dress identified on Exhibit D. 
 “Territory” means the United States, Canada, and each European country, territory, and possession that is specified on Exhibit C and is subject to and governed by the CE medical products rules under European
Union Medical Device Directive 93/42/EEC. The Territory may be expanded to include other countries, territories, or possessions that subsequently become subject to and governed by the CE medical products rules under European Union Medical Device
Directive 93/42/EEC with the written consent of both parties. The European countries, territories, and possessions specified on Exhibit C are sometimes collectively referred to as the “EC Countries.” 
 “Training Product Sample” means a unit of Company Product provided that is marked “Not for Commercial Sale” in a
manner agreed upon by the parties. 
 Other Defined Terms. Each of the following terms shall have the respective
meaning ascribed to such term in the section of this Agreement set forth opposite such term below: 
  

			
	 	  	 Section

	 “Agreement”
	  	Preamble
	 “CGMP”
	  	6.1
	 “Blocking Intellectual Property”
	  	8.4(c)
	 “Regulatory Approval Program”
	  	3.1
	 “Regulatory Approval Plan”
	  	3.1
	 “Complaint“
	  	6.8(a)
	 “Complaint Evaluation“
	  	6.8(b)

  

 – 3 – 

			
	 	  	 Section

	 “Development Agreement”
	  	8.4(b)
	 “Development Effort Data” 
	  	11.3
	 “Effective Date“
	  	Preamble
	 “Enhancements”
	  	8.4(a)
	 “Enhancements Notice”
	  	8.4(a)
	 “Indemnifying Party“
	  	10.2
	 “Indemnitees“
	  	10.2
	 “Losses“
	  	10.1(a)
	 “Prior Forecast”
	  	5.3(b)
	 “Process Complaint”
	  	6.8(c)
	 “Process Related Recalls”
	  	6.10(b)
	 “Product Development Meeting”
	  	8.4(a)
	 “Product Information”
	  	8.1
	 “Program”
	  	8.4(b)
	 “QSR”
	  	6.1
	 “Supplier“
	  	Preamble
	 “Term“
	  	11.1
	 “Transfer Price”
	  	5.12(a)

 2. LICENSE GRANT & PAYMENT 
 2.1 License Grant. Supplier hereby grants to BioForm an exclusive license under the BSA Patents and Proprietary Rights solely to develop, in
cooperation with Supplier, and to use, distribute, market, and sell, but not to make or manufacture, Company Product within the Field in the Territory. BioForm may sublicense rights to use, distribute, market, and sell under the license grant to
Affiliates who agree to be bound by the license and distribution limitations contained in this Agreement. 
 2.2 Considerations. As
compensation for the license grant contained in Section 2.1, BioForm shall (a) pay Supplier a one-time payment of $500,000 upon the execution of this Agreement, (b) pay Supplier any and all milestone payments coming due under
Section 3.3, and (c) purchase Company Product exclusively from Supplier in the manner provided herein. 
 3. DEVELOPMENT AND REGULATORY
APPROVALS 
 3.1 Development in the Field by BioForm. BioForm will use reasonable efforts to promptly design, fund, and conduct a
program intended to gain required Regulatory Approvals to market and sell Company Product in the United States, Canada, and the EC Countries for at least one indication within the Field, such as endoscopic brow lifts, that is reasonably acceptable
to Supplier, which acceptance will be communicated prior to the initiation of the program and will not be unreasonably withheld or delayed (the “Regulatory Approval Program”). BioForm will use reasonable efforts to execute
the Regulatory Approval Program in accordance with the Regulatory Approval Program, as such program may be amended from time to time. In connection with such clinical development activities: 
 (a) BioForm will bear all costs of the Regulatory Approval Program, including the cost of regulatory submissions, clinical trials, and activities to
support approval by the applicable Regulatory Authority in the United States, Canada, and the EC Countries except that BioForm shall not be required to reimburse Supplier for any costs or expenses incurred by it or its Affiliates, contractors, or
agents in connection with the non-financial assistance and cooperation that are provided free of charge under Section 3.2(b) and 3.2(c). BioForm will be responsible for the preparation of regulatory documents and submissions to the FDA in
connection with the Regulatory Approval Program. 
  

 – 4 – 

 (b) BioForm will develop a reasonably detailed written project timeline with milestones and resource
commitments for the Regulatory Approval Program (the “Regulatory Approval Plan”) that is reasonably acceptable to Supplier, which acceptance will not be unreasonably withheld or delayed, within 60 days after execution of this
Agreement. The Regulatory Approval Plan will establish: (i) the scope and time frame of the development activities that will be performed, (ii) development objectives, work plan activities, and time schedules with respect to the Regulatory
Approval Program, (iii) the obligations of the parties with respect to the Regulatory Approval Program, (iv) a budget for the various activities to be performed, and (v) a non-binding estimate of quantities of Company Product supply
needed for use as part of the Regulatory Approval Program. Attached as Exhibit 3.1(b) is a preliminary Regulatory Approval Plan developed by BioForm that will be superseded by the Regulatory Approval Plan but will serve as BioForm’s acting
Regulatory Approval Plan until the final Regulatory Approval Plan is completed and accepted by Supplier in the manner provided above, and such approval shall not to be unreasonably withheld, conditioned or delayed. Supplier agrees to accept any
Regulatory Approval Plan that is consistent with the preliminary Regulatory Approval Plan, provides for at least the same level of financial and resource commitment from BioForm as the preliminary Regulatory Approval Plan, and maintains, subject to
delays beyond the control of BioForm, substantially the same timeline as the preliminary Regulatory Approval Plan. 
 (c) Supplier shall
supply BioForm, at Supplier’s cost, a reasonable amount of Company Product for the Regulatory Approval Program, as contemplated by the Regulatory Approval Plan. 
 3.2 Regulatory Approvals. BioForm shall be responsible, at its expense, for obtaining, maintaining, and complying with all regulatory requirements, excluding requirements for manufacturing, and approvals
(including all Product Approvals) necessary or useful to market and sell Company Product in the Field within any jurisdiction of the Territory in which BioForm will market or sell Company Product. All regulatory approvals shall be obtained in the
name of and owned by BioForm. In pursuing such approvals: 
 (a) BioForm shall permit Supplier to review and comment upon BioForm’s
regulatory and clinical trial plans for the Territory. BioForm shall also be responsible for making all applicable regulatory filings. 
 (b)
Supplier will provide BioForm with non-financial assistance and cooperation in support of the Regulatory Approval Program, as reasonably requested by BioForm. Such assistance will include reasonable consultation with Supplier’s employees,
consultants, and agents on technical and regulatory matters, including acting as the sponsor of any potential premarket application supplements or other regulatory filings, and providing access to relevant historical research, development, clinical,
and regulatory files necessary for implementation of the Regulatory Approval Program and the submission of related premarket applications. 
 (c) Supplier shall permit BioForm to use any data owned by Supplier to support each premarket or regulatory application being made by BioForm for Company Product in the Field in the Territory. Supplier shall also permit BioForm to reference
such data in submissions to each Regulatory Authority and permit the Regulatory Authority to use such data in its reviews. Supplier shall update the data submissions it makes under this Section 3.2 and provide BioForm with all new data promptly
after the same is developed, assembled, or comes to the attention of Supplier. BioForm will provide the same rights and privileges to Supplier with respect to data owned or generated by or on behalf of BioForm in connection with the Company Product.
Information provided by either party pursuant to this Section 3.2(c) is subject to the confidentiality provision in Section 12.7. 
 (d) During the period beginning on the Effective Date and ending upon completion of the Regulatory Approval Program, at Supplier’s request, BioForm will provide Supplier with a reasonably detailed written report summarizing the
progress of the Regulatory Approval Program once each calendar 
  

 – 5 – 

 
quarter and, at Supplier’s request, meet with representatives of Supplier in person or by phone no more frequently than once per calendar quarter to
discuss progress with the Regulatory Approval Program. BioForm shall review with Supplier clinical trial protocols and the selection of clinical sites of any clinical trial to be conducted with respect to Company Product. BioForm will own all data
generated by or for BioForm or its Affiliates in the Regulatory Approval Program, except for data generated by Supplier, which data Supplier shall own. 
 (e) Supplier shall provide to BioForm, at Supplier’s expense, copies of its existing scientific, medical, clinical, regulatory technical, marketing, and other data related to the BioGlue product to support
BioForm’s clinical, regulatory, or marketing activities. BioForm shall provide to Supplier, at BioForm’s expense, summaries of its scientific, medical, clinical, regulatory technical, marketing, and other data related to the Company
Product to support Supplier clinical, regulatory, or marketing activities related to BioGlue Surgical Adhesive. 
 (f) BioForm will not be
liable for any costs associated with Supplier’s efforts in connection to maintaining and complying with all applicable regulatory requirements in the ordinary course of business for any product (including the BioGlue Surgical Adhesive or
Company Product). 
 3.3 Approval Milestone. BioForm shall pay to Supplier a milestone payment equal to $500,000 upon BioForm
receiving the first PMA approval from the FDA to market and sell the Company Product in any application within the Field in the United States. 
 4.
DISTRIBUTION AND PURCHASE 
 4.1 Appointment. Subject to the terms and conditions set forth in this Agreement, Supplier hereby
appoints BioForm as Supplier’s exclusive distributor of Company Product in the Field within the Territory for the Term, and BioForm hereby accepts such appointment. BioForm may appoint Affiliates as sub-distributors, but only those Affiliates
to whom they have granted sublicense rights under Section 2.1. Supplier acknowledges and agrees that it shall not be entitled to any compensation for the appointment contained in this Section 4.1 other than payment of the purchase price
for Company Product in accordance with Section 5.6 and payments due under Section 3.3. 
 4.2 Distribution Relationship;
Limitations on Supplier Activities. During the term of this Agreement, Supplier agrees to sell Company Product for use in the Field within the Territory exclusively to BioForm. Subject to the last sentence of this Section 4.2, Supplier
agrees (a) not to provide or sell any SA Product in the Field in the Territory for or to any third party if Supplier knows or has reason to believe that such SA Product will be provided, distributed, or sold anywhere in the Territory for use in
the Field; and (b) to use its commercially reasonable efforts to prevent the sale of any SA Product to customers for resale or distribution in the Field within the Territory by any party other than BioForm or its Affiliates, including
commercially reasonable efforts requested by BioForm, to prevent such unauthorized sales activity. The foregoing provisions of this Section 4.2 shall not be deemed to prohibit Supplier from developing or commercializing any SA Products
(including the BioGlue Surgical Adhesive) or any other product for any application outside the Field (whether inside or outside the Territory) or outside the Territory (whether or not within the Field). Supplier shall not be obligated under this
Section 4.2 from and after such time, if ever, as BioForm is in breach of its obligations under Section 4.5 and has not cured such breach within 60 days of written notice from Supplier notifying BioForm of such breach. 
 4.3 No Other Distributors. Supplier represents and warrants that, except to the limited extent disclosed on Exhibit 4.3, it does not currently
have any other agents, representatives, or distributors entitled to market, sell, or distribute SA Product in the Field within the Territory. Supplier represents and warrants that, except to the limited extent disclosed on Exhibit 4.3, there is no
restriction, covenant, or agreement to which it 
  

 – 6 – 

 
is a party or by which it is bound that would prevent or delay Supplier from providing to BioForm the exclusive distribution rights contained in this
Agreement, and Supplier agrees that it will not, directly or indirectly, undertake any action, omit to take any action, or enter into any agreement that will prevent or delay BioForm from the enjoyment by BioForm of the full benefits of exclusive
distribution relationship provided in this Agreement. Supplier will 4.4 use commercially reasonable efforts to amend the agreement disclosed on Exhibit 4.3 of any distributor that markets SA Product into the Field so as to prohibit the distributor
from distributing SA Product in the Field in the Territory during the term of this Agreement; and 4.5 terminate, or allow to expire, each agreement disclosed on Exhibit 4.3 in accordance with its terms if the agreement cannot be amended to prohibit
the third party from distributing SA Product in the Field in the Territory during the term of this Agreement. BioForm agrees not to contact any party to an agreement disclosed in Exhibit 4.3 without the prior written consent of Supplier. Supplier
will use its reasonable best efforts to complete the efforts required of Supplier by this Section 4.3 before the earlier of BioForm receiving PMA Approval to distribute Company Product in the United States or BioForm commencing active
distribution and promotion of Company Product in Canada or the EC Countries. 
 4.4 Marketing and Sales. All business decisions
concerning the sales and marketing of Company Product for use in the Field in the Territory, including the price, other sale terms, kitting practices, and promotion thereof, will be within the sole discretion of BioForm. Upon Supplier’s
reasonable request, but no more frequently than twice per calendar year, BioForm will discuss with Supplier BioForm’s marketing plans for Company Product in the Territory. Within 30 calendar days following the end of each calendar quarter,
BioForm will also provide Supplier with a written report of the following items during the prior calendar quarter in each of the United States, Canada, and the EC Countries (a) the volume of all sales of Company Product, (b) the total
revenue for all sales of Company Product, and (c) the average selling price of Company Product. BioForm will provide Supplier with an annual evaluation of the current and expected market situations with respect to Company Product in the
Territory in the Field. This evaluation will be provided to Supplier in January of each calendar year of this Agreement. 
 4.5 Limitation
on Activities of BioForm. Throughout the term of this Agreement, BioForm agrees (a) to offer for sale Company Product only for use in the Field within the Territory; (b) not to provide or sell any Company Product to any third party
that will provide, distribute, or sell the Company Product anywhere outside the Territory or for use outside the Field if BioForm knows or has reason to believe that such Company Product will be provided, distributed, or sold anywhere in the outside
Territory or for any use outside the Field; and (c) to use commercially reasonable efforts to prevent the resale or distribution of any Company Product to customers for resale or distribution outside the Field or the Territory by any party,
including commercially reasonable efforts requested by Supplier, to prevent such unauthorized sales activity. 
 4.6 Commercially
Reasonable Sales Efforts. Notwithstanding the terms of Section 4.4, BioForm shall use commercially reasonable efforts, consistent with its ordinary course of conduct, to commercialize, market, and sell Company Product for use in the Field
in the Territory during the term of this Agreement so long as Supplier supplies Company Product to BioForm in accordance with the terms of this Agreement provided that (a) BioForm shall not be required to use any level of efforts to sell,
market, or distribute Company Product in any jurisdiction prior to receipt of all Product Approvals reasonably deemed by BioForm to be necessary for the marketing and sale of Company Product in such jurisdiction; and (b) whether certain efforts
by BioForm are deemed to be “commercially reasonable” with respect to Company Product shall be determined in light of all relevant factors in the relevant jurisdictions including (i) BioForm’s reasonable estimate of the market
potential and rate of market growth of Company Product (including anticipated profit margin and the perceived market size); (ii) the level of Product Approval for Company Product in each jurisdiction (including the extent of the indications, if
any, within the Field for which Company Product has been approved); (iii) in BioForm’s reasonable estimation, whether or not the sale of Company Product infringes or could infringe the Patent Rights of third persons in the Territory;
(iv) the competitive position of Company Product vis-à-vis other products that may be marketed and sold for the same indications, including 

  

 – 7 – 

 
with respect to the safety, efficacy, and cost of Company Product when compared to such other products; and (v) the availability and supply of Company
Product for distribution. BioForm’s reasonable commercial efforts may include one or more of the following (1) promoting Company Product at major medical trade shows attended by plastic surgeons, facial plastic surgeons, ENT surgeons,
occuloplastic surgeons and dermatologists, (2) training, educating, supporting and maintaining representatives to market and sell Company Product in the Territory within the Field, or (3) applying reasonable financial, personnel and
facilities resources in support of its commercialization efforts. For purposes of determining whether or not BioForm is complying with its obligations under this Section 4.6, BioForm’s sales and marketing efforts for Company Product in all
relevant jurisdictions within the Territory shall be considered in the aggregate, and not by separate jurisdiction. 
 4.7 Marketing
Costs. Except as otherwise expressly provided in this Agreement, BioForm shall bear all expenses for marketing and selling Company Product in the Field in the Territory. 
 4.8 Product Differentiation. In order to appropriately distinguish Company Product sold by BioForm from BioGlue Surgical Adhesive sold by
Supplier, BioForm will (a) market and distribute Company Product exclusively under a new and separate brand and name approved in advance by Supplier, which approval shall not be unreasonably withheld or delayed, and (b) refrain from
actively marketing any connection between the Company Product and the BioGlue Surgical Adhesive. BioForm may make references to the safety of the BioGlue Surgical Adhesive in response to inquiries but not in any marketing communications or
materials. The provisions of this Section 4.8 shall not apply to activities performed by BioForm in connection with conducting clinical trials or regulatory filings as outlined in the Regulatory Approval Program or Regulatory Approval Plan in
accordance with Section 3.2. For purposes of clarification, responding to questions regarding commonalities between the BioGlue Surgical Adhesive and the Company Product will not be considered “active marketing” that violates
Section 4.8(b). Notwithstanding the foregoing, the parties will enter into good faith negotiations regarding an alternate brand and name strategy for the Company Product, including the possibility of incorporating the BioGlue brand, name and
trademark or derivations thereof into the brand and name for the Company Product. 
 4.9 Right of First Negotiation. Supplier agrees
to consider BioForm as a potential exclusive distributor in the Territory of any SA Product it desires to distribute within the Field. This undertaking shall require Supplier to first disclose the potential SA Product to BioForm in writing prior to
disclosure to other parties. If BioForm notifies Supplier in writing that it desires to negotiate for exclusive distribution rights within the Field and Territory for the disclosed SA Product within [****] after notice to BioForm of the availability
of such SA Product, Supplier shall enter into good faith negotiations with BioForm to determine commercially reasonable terms for such rights. Such discussions shall be exclusive for a period of [****]. Potential SA Product information disclosed
pursuant to this Section 4.9 shall be considered Supplier Confidential Information under Section 12.7. 
 5. PURCHASE OF PRODUCTS AND TERMS OF
SALE 
 5.1 Exclusive Purchase and Supply Relationship. BioForm agrees to purchase Company Product exclusively from Supplier in
accordance with the terms of this Agreement for so long as Supplier supplies the Company Product in accordance with the terms of this Agreement. 
 5.2 Forecasts. BioForm agrees to provide Supplier, to the extent practicable, at least six months prior to the date of anticipated first commercial release of any Company Product and at least 30 calendar days prior to the beginning
of each calendar quarter, a 12-month rolling forecast (limited to months during the Term) of its intended Company Product purchases. Except as set forth in Section 5.3(a), all forecast information shall be for informational purposes only and
shall not be a commitment to purchase. All forecasted amounts are for delivery of Company Product at the beginning of the month for which the forecast is made. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 8 – 

 5.3 Purchase Orders. BioForm shall submit to Supplier purchase orders for Company Product that
shall, at a minimum, identify the Company Product and set forth the quantities, price, delivery dates, and shipping instructions and shipping addresses for the Company Product ordered. Minimum purchase quantity shall be five units of Company
Product. 
 (a) Firm Commitments. With each rolling forecast submitted to Supplier, BioForm shall submit binding purchase orders to
cover one hundred percent (100%) of the Product orders included in the forecast for the initial three-month period of such forecast. Further, BioForm commits to purchase at least fifty percent (50%) of the Company Product orders forecast for the
immediately subsequent three month period of each rolling forecast submitted to Supplier. Company Product orders forecast for the remaining period of the forecast shall be non-binding. 
 (b) Purchase Order Acceptance. Each purchase order shall be deemed to have been accepted by Supplier, upon receipt in a manner that provides proof
of delivery, if the order quantity for that quarter is within [****] of the amount of Company Product set forth for that quarter in the forecast submitted by BioForm to Supplier before the beginning of the immediately prior quarter (the “Prior
Forecast”) and within the agreed-upon lead-time for such Company Product. Each accepted purchase order shall give rise to a contract between BioForm and Supplier for the sale of the Company Product units ordered and shall be subject to and
governed by the terms of this Agreement. The terms and conditions of this Agreement shall govern and supersede any additional or contrary terms set forth in BioForm’s purchase order or any Supplier or BioForm acceptance, confirmation, invoice,
or other document unless duly signed by an officer or designee of both BioForm and Supplier expressly stating and identifying which specific additional or contrary terms shall supersede the terms and conditions of this Agreement. 
 (c) Order Limitations. The amount of the initial purchase order and initial forecast for Company Product shall be agreed to by BioForm and
Supplier. Later forecasts shall require Supplier’s agreement only if they increase Company Product forecasts for any quarter by more than [****] of the amount forecasted in the Prior Forecast. In the event the purchase orders placed by BioForm
for delivery within any quarter is greater than [****] of the amount of Company Product set forth in the Prior Forecast, Supplier shall not be obligated to supply any such excess above [****] however, Supplier shall use its commercially reasonable
efforts to supply such excess. 
 5.4 Product Specifications; Packaging and Labeling. All Company Product delivered by Supplier
hereunder shall be in full compliance with Product Specifications, shall be labeled specifically for BioForm, and shall be ready for end-user sale, including all packaging, labeling, instructions-for-use, and sterilization, as approved by BioForm.
BioForm will develop and implement packaging and labeling for Company Product, subject to applicable regulatory requirements and consent of Supplier, which consent shall not be unreasonably withheld or delayed, to clearly differentiate Company
Product from BioGlue Surgical Adhesive products sold by Supplier. Supplier shall ensure that all Company Product shall be labeled in accordance with the procedures specified from time to time by BioForm and BioForm shall have final approval over all
packaging and labeling for Company Product, except for the consent provided for in the immediately preceding sentence. BioForm maintains the right to over-label Company Product as it deems necessary, but shall not utilize Supplier Trademarks
except in accordance with Section 7.1, and shall provide Supplier with copies of any additional labels used by BioForm. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 9 – 

 5.5 Obligation to Stock and Supply 
 (a) Supplier shall manufacture, sell, and deliver Company Product to BioForm and BioForm shall purchase Company Product from Supplier in accordance with
this Agreement and the related purchase orders on the date specified for delivery in the purchase order (which date shall not be earlier than 30 calendar days after the date of the purchase order). 
 (b) Supplier will use its reasonable best efforts to maintain the ability to supply all Company Products that Supplier is required to deliver pursuant to
Section 5.2. If Supplier becomes or projects that it may be incapable of making such required deliveries of Company Products, subject to normal lead-time requirements, Supplier agrees to meet with BioForm and agree to a reasonable allocation
plan to assure BioForm a fair allocation of Supplier resources to meet BioForm’s requirements for Company Product. Supplier will provide BioForm with as much notice as reasonably possible if it anticipates or has reason to believe that
Supplier’s output of the Company Product will not be sufficient to supply all Company Products that Supplier is required to deliver pursuant to Section 5.2 and 5.3. 
 (c) Supplier shall maintain at all times a supply of raw material inventory necessary to manufacture Company Product for three months as forecasted to be
purchased by BioForm based on the most recent forecast. In addition, Supplier shall maintain at all times manufacturing capacity and raw materials sufficient to supply at least [****] estimated quantity of purchase for the first six months of the
most recent forecast. 
 (d) BioForm shall maintain at all times a supply of Company Product finished inventory equal to approximately [****]
supply. 
 5.6 Payment. Supplier shall invoice BioForm for Company Product delivered to BioForm in accordance with this Agreement and
purchase orders at the prices described in Section 5.12. BioForm shall pay for Company Product within 40 calendar days after the date of Supplier’s invoice (provided that the invoice date is no earlier than the date that shipment is
received), unless BioForm has not accepted the delivery in accordance with Section 5.9. Late payments shall bear interest at the prime rate per annum. In the event that Supplier is required to institute any action to enforce collection of any
amounts due to Supplier from BioForm under this Agreement, BioForm shall pay, in addition to all amounts due, all reasonable out-of-pocket costs and expenses incurred by Supplier in connection with the collection of such amounts, including
reasonable attorneys’ fees and disbursements. 
 5.7 Samples 
 (a) Upon BioForm’s request, Supplier will sell to BioForm Bulk Product Sample units for use by BioForm only as samples used in sales demonstrations
and trade shows and for regulatory purposes but not in surgical procedures involving humans. The number of Bulk Product Sample units to be sold to BioForm under this Section 5.7 during any calendar quarter shall not exceed [****] of the
aggregate number of product units ordered by BioForm during the immediately prior calendar quarter. Notwithstanding the foregoing, Supplier shall sell to BioForm [****] Bulk Product Sample units for the EC Countries and [****] Bulk Product Sample
units for the United States, respectively, in the first six months following the commercial launch of Company Product in such regions. The price for each Bulk Product Sample unit will equal [****] per unit. 
 (b) Upon FDA PMA approval and upon BioForm’s request, Supplier will sell to BioForm Training Product Samples at [****] per Training Product Sample
unit for use by BioForm only as samples in the Territory. Training Product Samples may be used in sales demonstrations and trade shows, for regulatory purposes, for clinical in-service training, and for demonstration on humans so long as there is no
charge for such use by BioForm. Supplier shall sell Training Product Sample units to BioForm for use as follows: (i) up to [****] Training Product Sample units following the commercial launch of Company Product 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 10 – 

 in the United States and (ii) up to [****] Training Product Sample units during each quarter for the seven quarters
following FDA PMA approval. 
 (c) BioForm may not sell any Bulk Product Sample units or Training Product Samples. If requested by Supplier,
BioForm shall certify in writing that sample product units were used only in compliance with this Section 5.7. 
 5.8 Delivery
Terms. All deliveries of Products shall be F.O.B. Supplier’s manufacturing facility. Supplier shall have no further responsibility for Products after, and all risk of damage to or loss or delay of Products shall pass to BioForm upon,
delivery by Supplier at the F.O.B. location to the common carrier specified by BioForm or, in the event that no carrier shall have been specified by BioForm on or before the date 15 days prior to the requested shipment date, a common carrier
reasonably selected by Supplier, or in the event that BioForm delays shipment more than four business days following the delivery date stated in the applicable purchase order. BioForm shall be responsible for all shipping, handling, insurance, and
inventory holding (from the third business day following such delivery) costs resulting from Product deliveries in accordance with this Section 5.8. BioForm agrees to store, transport, and deliver Company Product in a manner that ensures
Company Product is delivered to the end user in good condition. Supplier shall deliver all Company Products to BioForm free and clear of all liens and encumbrances or other defects in title. 
 5.9 Acceptance 
 (a) Each shipment of
Company Product from Supplier to BioForm shall contain such quality control certificates reasonably requested by BioForm certifying that the Company Product units shipped conform to the Product Specifications. Notwithstanding any prior inspection or
payments, all Company Product will be subject to final inspection and acceptance at BioForm’s designated destination point within fifteen business days after delivery. BioForm shall notify Supplier within fifteen business days after delivery of
any apparent defective material or workmanship or non-conformity of any Company Product unit to the Product Specifications, purchase order, or, if apparent, the requirements of Section 6.1. If BioForm fails to so notify Supplier, BioForm will
be deemed to have accepted the Company Product units received; provided, that the warranty set forth in Section 9.2 shall survive acceptance of the Company Product by BioForm. 
 (b) Without prejudice to any other right or remedy of BioForm, in case any item is defective in material or workmanship, or otherwise not in conformity
with the Product Specifications, the requirements of BioForm’s purchase order, or the requirements of Section 6.1, BioForm will have the right to reject it. Any item that has been rejected must be replaced by and at the expense of Supplier
promptly after notice. BioForm will not be required to pay for any rejected item, or its shipping costs or any other costs related thereto. BioForm will return all rejected Company Product to Supplier at Supplier’s expense. Supplier shall
investigate the cause for the rejection and provide to BioForm in writing all proposed corrective actions associated with the cause for rejection. 
 5.10 Changes. Supplier shall not make any changes to Company Product (including materials, packaging, and directions for use), the BSA Specifications, the Product Specifications, raw materials, component suppliers, or manufacturing
process for Company Product, which in any case could reasonably be expected to affect the form, fit, function, regulatory status, or efficacy of the Company Product or patient safety, unless approved by BioForm in writing in advance, which approval
may not be unreasonably denied. Without limiting the foregoing, all such changes (including changes required by law) shall be submitted to BioForm no later than 60 calendar days prior to Supplier’s proposed date of implementation for such
change. Unless BioForm notifies Supplier in writing that it disapproves of such change during the 60-calendar day period or if such a proposed change is otherwise required by law, regulation, or Regulatory Authority directive, Supplier shall be
authorized to implement such change and shall be responsible for properly 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 11 – 

 
communicating and implementing such change, including with respect to any of Supplier’s vendors. Without limiting the foregoing, the following changes
shall be deemed governed by this Section 5.10: (a) use of any nonconforming material in the manufacture of any Company Product in variance with the Product Specifications; (b) implementation of any Supplier-authorized temporary
deviation that could affect the handling, sterility, safety, or efficacy of any Company Product and be at variance with the Product Specifications; or (c) implementation of any Supplier-initiated corrective action that could affect the safety
or efficacy of the Company Product. The foregoing is not intended to limit Supplier’s ability to make changes to any product other than the Company Product (or any of its components). 
 5.11 Supply Interruption Notice. Supplier will notify BioForm immediately in writing upon becoming aware of any material obsolescence, supply
shortage, or other interruption or potential interruption in the supply of any material, component, or sub-assembly, in each case as it relates to Company Product. 
 5.12 Transfer Price 
 (a) Company Product Price. Except as otherwise provided for the purchase
of samples in Section 5.7 and subject to the terms of this Section 5.12, BioForm shall pay Supplier a transfer price (the “Transfer Price”) for any Company Product delivered to and not rejected by BioForm equal to
(i) until BioForm has ordered and accepted [****] units of Company Product in any calendar year, [****] per product unit; (ii) thereafter, until BioForm has ordered and accepted [****] units of Company Product in any calendar year, [****]
per product unit; and (iii) thereafter, for any remaining units of Company Product ordered and accepted in any calendar year, [****] per unit. 
 (b) Component Price. From time to time, BioForm may request to individually purchase components, such as applicator tips, of the Company Product for use in connection with the sale of Company Product. BioForm shall pay Supplier a
transfer price for any component in an amount to be negotiated in good faith between the parties. 
 (c) Adjustments to Transfer
Price. Additionally, the parties agree to use commercially reasonable, good faith efforts to negotiate adjustments to the Transfer Price if (a) requested by Supplier, and only if Supplier’s cost to manufacture Company Product [****]
since the Effective Date or latest prior price adjustment; or (b) requested by BioForm, upon the occurrence of a change in market dynamics that results in BioForm [****] since the Effective Date or latest prior price adjustment. 
 (d) No Limitation on Pricing. Nothing contained herein shall be deemed to limit in any way the right of BioForm to determine the prices at which,
or the terms on which, Company Product purchased by BioForm may be resold by BioForm. Supplier will be responsible for any royalties or fees payable by Supplier or BioForm to any third party with respect to any agreement concerning such third
party’s Intellectual Property or other proprietary rights associated with the import, export, use, sale, or distribution hereunder of any Company Product. 
 6. COMPLIANCE 
 6.1 Manufacturing Requirements. Supplier will manufacture Company Product in accordance with the
then-current (a) Product Specifications, (b) applicable regulations relating to current Good Manufacturing Practices and similar protocols required by the Act (“CGMP”), quality system regulations of the FDA
(“QSR”), including master device and lot history records, and ISO 13485 requirements (including appropriate certification), MDD requirements, CMDCAS requirements, and (c) other pertinent rules and regulations of
Regulatory Authorities that have approved sale of the Company Product. Upon the request of BioForm, Supplier shall provide BioForm with written evidence of compliance with the criteria set forth in the preceding sentence. During the Term, Supplier
will maintain, or cause to be maintained, the Company 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 12 – 

 
Product manufacturing facility’s registration as a certified medical device manufacturing facility with all applicable Regulatory Authorities or cause
such facility to be maintained such that the facility would pass an audit for compliance with CGMP and QSR. Supplier shall maintain ongoing quality assurance and testing policies sufficient to satisfy its obligations under this Agreement,
BioForm’s standard requirements for approval as a vendor as described in BioForm’s supplier quality system review policy, and Supplier’s standard quality assurance policies, copies of which are attached hereto. For seven years after
delivery to BioForm of each Company Product unit, or such longer period as may be required by CGMP and other applicable rules and regulations of any Regulatory Authority, Supplier shall (i) maintain traceability for each Company Product unit
including the manufacturing date and lot number of each Company Product unit and each component and material comprising each Company Product and (ii) provide BioForm a copy of such records upon BioForm’s written request. 
 6.2 Regulatory Communications. Each party shall promptly notify the other and provide to the other a copy or transcription, if available, of any
communication from any Regulatory Authority relating to Company Product, the marketing thereof, or any related matter (including copies of all Product Approvals) and shall keep the other party reasonably apprised of regulatory interactions and
similar activities with governmental authorities and international bodies in connection with Company Product anywhere in the Territory. 
 6.3 Traceability Program. BioForm shall be responsible for maintaining medical device vigilance systems in the Territory as required by laws applicable to distributors of products such as the Company Product, and shall provide
Supplier with reasonable access to such records. 
 6.4 Notices. Each party shall notify the other immediately by fax, with confirming
notice via overnight delivery, as soon as it becomes aware of any issue with Company Product or its testing, manufacture, labeling, or packaging, occurring within the Territory or outside of the Territory, including any issue relating to regulatory
compliance, safety or efficacy of Company Product or breach by the party of the terms of this Agreement. Without limiting the generality of the foregoing, each party will notify the other immediately if it becomes aware of any death or bodily injury
caused by a Company Product unit (or suspected to be caused by a Company Product unit) or any malfunction of Company Product occurring within the Territory or outside of the Territory or any regulatory or ISO inspections or other communications with
regulatory or ISO authorities related to the Company Product or that would in any way impact Company Product or the party’s performance of its responsibilities hereunder. 
 6.5 Compliance with Laws. Each party will comply with all laws and regulations in the Territory applicable to it that pertain to the testing,
manufacture, labeling, marketing, distribution, sale, or packaging of Company Product and in any other manner pertaining to the performance of its obligations under this Agreement, including the maintenance of ongoing quality assurance and testing
procedures to comply with applicable regulatory requirements. Each party will also comply with all laws and regulations applicable to it of the countries and jurisdictions in the Territory pertaining to the import, export, distribution, sales, and
marketing of Company Product. Without limiting the generality of the foregoing, each party will, as required by law of such party, (a) report to every applicable Regulatory Authority within any relevant time periods all events that are required
to be reported (including any death or serious bodily injury caused by a Company Product); and (b) deliver, within the permitted time periods, all annual or other periodic reports required to be delivered to every applicable Regulatory
Authority. 
 6.6 BioForm Inspection Rights; Regulatory Co-operation; Suppliers 
 (a) BioForm shall have the right to have its representatives present at the plant or plants at which Company Product is manufactured during normal
business hours to conduct an initial and periodic inspections of such facilities and manufacturing procedures for compliance with CGMP and QSR, the Product 

  

 – 13 – 

 
Specifications and BioForm’s quality assurance requirements and to inspect Supplier’s inventory of Company Product, work-in-process, raw materials
to be used for Company Product, production records, design history file, quality manuals, regulatory dossiers, and such other matters as may be pertinent to proper quality assurance of Company Product to be delivered hereunder. BioForm agrees to
give Supplier a minimum of five business days’ prior notice of any such inspection and each non-employee BioForm representative may be required by Supplier to sign a confidentiality agreement. Supplier shall promptly use its best efforts to
take such action as is required to correct any deficiencies identified by BioForm relating to the production of Company Product. Supplier further agrees to use its best efforts to provide such documentation or conduct such analyses as BioForm may
reasonably request in connection with any regulatory submission or audit. 
 (b) At BioForm’s reasonable request, Supplier will perform
a quality system assessment of the vendors who provide Supplier with raw components/materials, sub-assemblies or contract services for any Company Product. 
 6.7 Regulatory Audit. Supplier will permit authorized representatives of any Regulatory Authority to inspect Supplier’s plant and production facilities relating to or used in connection with the
manufacture of Company Product and will promptly notify BioForm when Supplier receives notice of any such inspection. Supplier will advise BioForm of the findings of any regulatory inspection and will promptly take the necessary steps to correct any
compliance deficiencies found by the Regulatory Authority relating to the production of Company Product. Supplier further agrees to use its reasonable best efforts to provide to BioForm such documentation or conduct such analyses as BioForm may
reasonably request in connection with any regulatory submission or audit concerning Company Product. BioForm will permit authorized representatives of any Regulatory Authority to inspect BioForm’s facilities relating to distribution of Company
Product and will promptly notify Supplier when BioForm receives notice of any such inspection. BioForm will advise Supplier of the findings of any regulatory inspection and will promptly take the necessary steps to correct any compliance
deficiencies found by the Regulatory Authority relating to BioForm’s activities with Company Product. 
 6.8 Complaints. BioForm
shall be responsible for all Company Product-related Complaint handling activities, evaluations, analyses, and regulatory communications. BioForm will enter all Complaints, as well as recommendations and analyses of Supplier, into BioForm’s
Complaint handling system. In connection with such Complaint activities: 
 (a) “Complaint” means any written,
electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution (marketed). 
 (b) “Complaint Evaluation” means a documented process for determining the root cause (or the most probable cause) of a Complaint.

 (c) At BioForm’s request, Supplier will cooperate and perform Complaint Evaluations for Complaints that may be the result of
Supplier’s actions (a “Process Complaint”) in order to determine any required corrective actions. Supplier will maintain records of such investigations as required by CGMP. Supplier has a period of seven calendar days
from the time it receives a Process Complaint from BioForm to perform a preliminary investigation that evaluates the root cause of the Complaint and makes a corrective action recommendation. Supplier will inform BioForm immediately of the results of
any such investigation and Supplier’s recommendations. BioForm will return to Supplier the Company Product unit that is the subject of the Complaint if such Company Product has been made available to BioForm. Supplier will also maintain a cross
reference system from Supplier’s complaint handling system to BioForm’s complaint handling system. Supplier will take reasonable actions to complete all corrective actions in connection with a Process Complaint within 90 calendar days.
BioForm acknowledges that some corrective actions may take 

  

 – 14 – 

 
more than 90 calendar days to complete. Upon BioForm’s request, Supplier will provide periodic updates until all corrective actions are complete.
Supplier will provide BioForm with a follow-up report on the effectiveness of the corrective actions within a reasonable time period. Without limiting the foregoing, to the extent required by applicable law, Supplier will report all Complaints to
the relevant Regulatory Authority in compliance with its obligations under Section 6.5. 
 (d) BioForm will promptly notify Supplier of
any corrective actions generated by BioForm relating to Company Product. Any such corrective actions that require action by Supplier will be specifically noted by BioForm and Supplier will provide a written response to BioForm within 15 calendar
days. BioForm may elect to increase this time period at its option. 
 6.9 Quality Plan. Supplier shall establish a quality plan which
will define the quality practices, the resources, and the activities relevant to Company Product and will periodically notify BioForm of any updates or revisions to the Quality Plan. This plan must be approved in writing by BioForm, which approval
will not be unreasonably withheld, conditioned or delayed. 
 6.10 Product Recalls 
 (a) If, in the judgment of Supplier or BioForm, any Company Product defect or any government action requires a recall of, or the issuance of an advisory
letter regarding, any Company Product, either party may undertake such recall or issue such advisory letter after consultation with the other party. Each party shall notify the other party in a timely manner prior to making any recall or issuing any
advisory letter. The parties shall endeavor to reach an agreement prior to making any recall or issuing any advisory letter regarding the manner, text, and timing of any publicity to be given such matters in time to comply with any applicable legal
or regulatory requirements, but such agreement will not be a precondition to any action that either party deems necessary to protect users of Company Product or to comply with any applicable governmental orders, regulations, or mandates. The parties
agree to provide reasonable assistance to one another in the event of any recall or issuance of any advisory letter. BioForm shall have the right to manage any recall within the Territory so long as such management does not prevent Supplier from
exercising its rights under this Section 6.10. 
 (b) In the event of a recall of Company Product, Supplier shall correct noted
deficiencies relating to its manufacture, packaging, testing, labeling, and Supplier’s storing or handling of Company Product (“Process Related Recalls”), if applicable, or cause the vendor of any material, component, or
sub-assembly incorporated into such Company Product to do likewise with respect to such material, component, or sub-assembly and BioForm shall correct noted deficiencies related to matters for which it is responsible. For Process Related Recalls,
Supplier shall, at BioForm’s option, either, at its cost replace each unit of the Company Product recalled (including units held in inventory by BioForm or its customers) with a corrected Company Product within a reasonable period of time, or
refund the purchase price therefor. Supplier shall promptly pay or reimburse BioForm for all costs and expenses (including shipping, quality control testing, notification, and restocking costs) incurred by BioForm as a result of any recall or
advisory letter (unless resulting from a deficiency caused by BioForm, in which case BioForm will reimburse Supplier for Supplier’s costs and expenses associated with such recall). 
 7. TRADEMARKS; IMPROVEMENTS; INTELLECTUAL PROPERTY 
 7.1 Trademarks. Except as may otherwise be
agreed to by the parties in accordance with Section 4.8, BioForm shall have no right to use the Supplier Trademarks in connection with the promotion, marketing, sale, distribution, and delivery of Company Product or otherwise and BioForm shall
not otherwise use the Supplier Trademarks in connection with the promotion, marketing, sale, distribution, or delivery of any Company Product except as may be required to comply with applicable law or regulations relating to 
  

 – 15 – 

 
distribution within the Territory of Company Product, and Supplier hereby grants to BioForm a license to do so. Except as may otherwise be agreed to by the
parties in accordance with Section 4.8, BioForm agrees not to use, distribute, or market any BioForm Trademarks in connection with any Company Product or otherwise that are sufficiently similar to any Supplier Trademarks as to create confusion
between Company Product and the BioGlue Surgical Adhesive. 
 7.2 Infringement 
 (a) Each of BioForm and Supplier will notify the other party in writing of any infringement of a Proprietary Right in the Field and in the Territory or
unauthorized disclosure or use of any Confidential Information pertaining to the Company Product within 15 calendar days after it becomes aware of such infringement or unauthorized disclosure. Supplier shall have the exclusive right to determine
what action, if any, to take in response to any such unauthorized use and to take all legal action it deems necessary or advisable to eliminate or minimize the consequences of any infringement of a Proprietary Right in the Field and in the
Territory. 
 (b) Supplier shall permit BioForm to participate at its own cost in any legal action brought by Supplier to eliminate or
minimize the consequences of any infringement of a Proprietary Right in the Field in the Territory; provided that Supplier shall maintain the right to control the prosecution of such action. 
 (c) If BioForm elects to participate in the legal action, all proceeds realized upon any judgment or settlement regarding an action undertaken pursuant
to Section 7.2(a) with respect to infringement of Proprietary Rights (net of direct out-of-pocket fees and expenses relating thereto) in the Field in the Territory shall be shared equally by Supplier and BioForm with respect to infringement of
Patent Rights. 
 (d) If BioForm can demonstrate that an infringing product has gained a minimum of [****] share of the market addressed by
the Company Product in the Field in the Territory taken as a whole, the Transfer Price paid by BioForm to Supplier for Company Product will decrease by [****] per unit. Such decrease will remain in effect until a Favorable Conclusion is obtained.
For the purposes of this Agreement, a “Favorable Conclusion” is defined as a cessation of the infringement, withdrawal of the infringing product from the Field in the Territory, reduction of the infringing products market
share in the Field in the Territory to less than [****], or other compromise conclusion to the infringement that is reasonably acceptable to both BioForm and Supplier. If a Favorable Conclusion cannot be obtained the decreased Transfer Price set
forth in this Section 7.2(d) will remain for the Term of this Agreement. 
 7.3 Patent Prosecution. Supplier shall apply for,
prosecute, and maintain the BSA Patents in the Territory. Supplier shall keep BioForm reasonably informed as to the status of the prosecution and maintenance of the BSA Patents in the Territory and with respect to any actions regarding the BSA
Patents in the Territory. Payment of all fees and costs relating to the filing, prosecution, and maintenance of the BSA Patents shall be the responsibility of Supplier. 
 8. CERTAIN OBLIGATIONS OF SUPPLIER 
 8.1 Product Information. Supplier will assist BioForm in
creating product handling manuals, sales literature, promotional materials, training materials, videos, demonstration kits, and other applicable information for Company Product by sharing with BioForm similar information developed and used by
Supplier with its BioGlue Surgical Adhesive. The material shared (collectively, the “Product Information”) shall include information Supplier has that it believes will he helpful and appropriate in assisting BioForm in
formulating any other manuals, promotional materials, and warning labels deemed necessary or appropriate by BioForm for Company Product. Product Information shared may be used by BioForm solely for the purpose identified above. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 16 – 

 8.2 BioForm Materials. Portions of the Product Information may be incorporated into BioForm
materials used with Company Product but only in ways that avoid attribution to or association with Supplier or Supplier products other than Company Product. Supplier represents and warrants that the Product Information shall be accurate and complete
in all material respects, and undertakes to update any such Product Information when any information included therein becomes outdated, inaccurate, or misleading. BioForm acknowledges, however, that the Product Information relates specifically to
the BioGlue Surgical Adhesive and not the Company Product. BioForm shall have the right to produce, at its expense, promotional material, Company Product handling manuals, instructions for use, warning labels, and other written information relating
to Company Product that is based in whole or in part on the material supplied by Supplier subject to the limitations set forth above. BioForm reserves exclusive right and title in BioForm-created Company Product literature and documentation, subject
to Supplier’s retained rights in, and BioForm’s limited licensed rights to, any Product Information incorporated therein. 
 8.3
Training Advice and Assistance. Supplier will provide reasonable train-the-trainer technical assistance and training at Supplier’s facilities regarding Company Product for BioForm as BioForm reasonably requests. Supplier shall also
provide to BioForm other services or other support information to assist BioForm in marketing Company Product as BioForm reasonably requests. BioForm shall be responsible for all of its costs associated with obtaining the training and support
provided for under this Section 8.3. Supplier shall be responsible for the costs and expenses of its personnel incurred in connection with providing train-the-trainer technical assistance and training provided pursuant to this Section 8.3,
up to a maximum of [****] per year. 
 8.4 Product Development 
 (a) Supplier may develop enhancements it intends to incorporate into the BioGlue Surgical Adhesive during the term of this Agreement that have potential
application to the Company Product (“Enhancements”). Unless otherwise agreed by the parties, at least once every six months during the Term, representatives of each of BioForm and Supplier shall hold a meeting in
accordance with Sections 4.4 and 8.4 (the “Product Development Meeting”) at which Supplier will present Enhancements for BioForm to consider for application to the Company Product. At such Product Development Meeting, BioForm
will also present its marketing plans (pursuant to Section 4.4) for the period and any information or feedback that BioForm reasonably believes may lead to Improvements. Within 30 calendar days following each Product Development Meeting,
Supplier shall deliver a notice to BioForm (the “Enhancements Notice”) that shall describe the Enhancements that were presented by Supplier at such Product Development Meeting. Within 30 calendar days following receipt of the
Enhancements Notice, BioForm may notify Supplier in writing if BioForm elects that any Enhancement described in the Enhancements Notice shall become an Improvement. If BioForm does provide such notice to Supplier during such 30-calendar day period,
then BioForm and Supplier shall agree on a timeline for implementation of the Improvement in new Product Specifications for Company Product. If BioForm does not provide such a notice, said Enhancement shall not be implemented into the Company
Product. The Enhancements Notice may also describe any potential Enhancements presented by Supplier at the Product Development Meeting, but BioForm shall not be required to take any action under this Section 8.4 with respect to such potential
Enhancements until such time as they are presented by Supplier as Enhancements at a future Product Development Meeting. All Enhancements and potential Enhancement information provided by Supplier shall be considered Supplier Confidential
Information. 
 (b) From time to time, each party may request the other party to participate in joint projects to develop Improvements.
Neither party is obligated to participate in such projects, and in each 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 17 – 

 
instance, each party’s decision whether to participate will be made in such party’s sole discretion. If both parties mutually agree to participate
in such a project (a “Program”), the parties will promptly prepare a mutually agreeable written development agreement specifying the development activities to be performed by and the research and development tasks assigned to
each party (the “Development Agreement”). All allocation of Intellectual Property rights with respect to any Program will be set forth in writing in the Development Agreement. 
 (c) In the absence of a Development Agreement, (i) BioForm and Supplier shall retain joint ownership of Intellectual Property rights in which there
is joint inventorship by BioForm (or its Affiliates) and Supplier, as determined in accordance with United States patent law, with Supplier’s rights in such joint ownership being subject to the license rights of BioForm under this Agreement,
(ii) any Intellectual Property rights related to the Company Products, Enhancements, and Improvements that are created solely by employees or consultants of Supplier during the Term shall be considered to be Intellectual Property rights of
Supplier, subject to the license rights of BioForm under this Agreement, and (iii) any Intellectual Property rights related to the Company Products and Improvements that are created solely by employees or consultants of BioForm or any of its
Affiliates during the Term shall be considered to be Intellectual Property rights of BioForm. BioForm hereby grants to Supplier a perpetual, royalty free, world-wide, nonexclusive license to Supplier under such Blocking Intellectual Property to
make, use, and sell such Intellectual Property outside the Field. “Blocking Intellectual Property” for the purposes of Section 8.4(c)(iii) shall mean Intellectual Property necessary for Supplier to make, use, or sell SA
Product. 
 9. REPRESENTATIONS AND WARRANTIES 
 9.1 Mutual Representations and Warranties 
 (a) Supplier hereby represents and warrants that: 
 (i) it is a duly and validly organized and existing corporation in good standing under the laws of the state of Florida, and that it or its Affiliates
that may be performing its obligations under this Agreement are legally qualified to do business in each jurisdiction in which this Agreement may be performed and where its activities hereunder require such qualification, 
 (ii) the performance of this Agreement and the consummation of the transactions contemplated herein will not result in any breach, conflict, or
violation of any terms or provisions of, or constitute a default under, its Certificate of Incorporation or By-Laws, or other organizational documents, or any material agreement or instrument to which it is a party, by which it is bound, or to which
any of its property is subject, 
 (iii) all requisite corporate action has been taken for the due authorization, execution, delivery, and
performance of this Agreement by it, and this Agreement constitutes a legally binding obligation, enforceable against such party, in accordance with its terms, except insofar as enforceability may be limited by bankruptcy, insolvency,
reorganization, or similar laws affecting the rights of creditors generally, and 
 (iv) it is not a party to any litigation relating to, or
that could reasonably be expected to affect, its ability to perform its obligations under this Agreement. 
 (b) BioForm hereby represents
and warrants that: 
 (i) it is a duly and validly organized and existing corporation in good standing under the laws of the state of
Delaware, and that it or its Affiliates that may be performing its obligations under this Agreement are legally qualified to do business in each jurisdiction in which this Agreement may be performed and where its activities hereunder require such
qualification, 
  

 – 18 – 

 (ii) the performance of this Agreement and the consummation of the transactions contemplated herein will
not result in any breach or violation of any terms or provisions of, or constitute a default under, its Certificate of Incorporation or By-Laws, or other organizational documents, or any material agreement or instrument to which it is a party, by
which it is bound, or to which any of its property is subject, 
 (iii) all requisite corporate action has been taken for the due
authorization, execution, delivery, and performance of this Agreement by it, and this Agreement constitutes a legally binding obligation, enforceable against such party, in accordance with its terms, except insofar as enforceability may be limited
by bankruptcy, insolvency, reorganization, or similar laws affecting the rights of creditors generally, and 
 (iv) it is not a party to any
litigation relating to, or that could reasonably be expected to affect, its ability to perform its obligations under this Agreement. 
 9.2
Product Warranty. Supplier represents and warrants to BioForm that Company Product supplied to BioForm hereunder shall, during the applicable shelf life: (a) conform to the Product Specifications, (b) be manufactured, labeled,
packaged, and tested (while in the possession or control of Supplier) in accordance with applicable Product Approvals and applicable laws and regulations in each country or jurisdiction within the Territory for which Product Approval has been
obtained relating to the manufacture, labeling, packaging, and testing of Company Product, including those set forth in Section 6.1, (c) have a shelf life of at least two years when shipped to BioForm, and (d) be free and clear of
liens and encumbrances. 
 9.3 Non-Infringement. Supplier represents and warrants to BioForm that it knows of no Intellectual Property
rights of others that will be infringed by the development, manufacture, marketing, or sale of the Company Product by Supplier or BioForm as contemplated by this Agreement. 
 9.4 Title. Supplier represents and warrants to BioForm that Supplier has sufficient right, title, and interest in the BSA Patents and the
Proprietary Rights to perform its obligations under this Agreement and to grant BioForm the license and distribution rights that are granted in this Agreement. 
 10. INDEMNIFICATION AND LIABILITY 
 10.1 Infringement Indemnification 
 (a) Subject to the provisions of Section 10.3, Supplier shall defend, indemnify, and hold harmless BioForm, its subsidiaries, parent corporations,
Affiliates, officers, directors, independent contractors, partners, shareholders, employees, agents, and their respective successors and assigns from and against any claim, suit, demand, loss, damage, expense (including reasonable attorney’s
fees and those that may be asserted by a third party), or liability (collectively, “Losses”) arising from or related to an allegation that the development, manufacture, marketing, or sale of any Company Product in the
Territory infringes or misappropriates any Intellectual Property right of any third party, except for Losses that are the responsibility of BioForm pursuant to Section 10.1(b). If any Company Product is held to constitute an infringement or
misappropriation of any third party’s Intellectual Property right or if BioForm and Supplier concur that any Company Product constitutes an infringement or misappropriation, Supplier will at its expense either: (i) procure the right for
BioForm to continue distributing the Company Product in accordance with this Agreement at no additional cost to BioForm, (ii) replace the Company Product with a non-infringing and non-misappropriating equivalent product conforming to the
Product Specifications at no additional cost to BioForm, or (iii) modify the Company Product to make it non-infringing and non-misappropriating while conforming to the Product Specifications at no additional cost to BioForm. 
  

 – 19 – 

 (b) Subject to the provisions of Section 10.3, BioForm shall defend, indemnify, and hold harmless
Supplier, its subsidiaries, parent corporations, Affiliates, officers, directors, independent contractors, partners, shareholders, employees, agents, and their respective successors and assigns from and against any Losses arising from or related to
(i) an allegation that any BioForm Trademark used by BioForm in connection with the marketing or sale of Company Product infringes or misappropriates any trademark right of any third party, (ii) from any product description or claim made
by BioForm in writing or through electronic transmission that is not consistent with the product description and claims approved by Supplier, or (iii) a warranty claim asserted by any third party based on a warranty made in connection with
Company Product that was not approved in writing by Supplier. 
 10.2 Other Claims. Subject to the provisions of
Section 10.3, each of Supplier and BioForm (each, in such capacity, an “Indemnifying Party”) will defend, indemnify, and hold harmless the other party, its subsidiaries, parent corporations, Affiliates, officers,
directors, independent contractors, partners, shareholders, employees, agents, and their respective successors and assigns (collectively, in such capacity, the “Indemnitees”) from and against any Losses, including Losses
imposed upon or caused to be incurred by the Indemnitee(s) by any third party, arising from or related to (a) any material breach of such Indemnifying Party’s representations and warranties, covenants, or obligations under this Agreement;
or (b) any negligence or intentional misconduct by such Indemnifying Party (or its employees, agents, or representatives) in performing its obligations under this Agreement. The indemnification under the foregoing clause (b) shall not
apply in the event and to the extent that a court of competent jurisdiction determines that such Losses arose as a result of any Indemnitees’ negligence, intentional misconduct, or breach of this Agreement. 
 10.3 Procedure. A party seeking indemnification shall promptly notify the other party in writing of a claim or suit; provided, that a
party’s failure to give such notice or delay in giving such notice shall not affect such party’s right to indemnification under this Section 10 except to the extent that the other party has been prejudiced by such failure or delay.
Neither party has any obligation to indemnify the other party in connection with any settlement made without the Indemnifying Party’s written consent, which consent shall not be unreasonably withheld. The Indemnitee has the right to participate
(i) at its own expense in the claim or suit with counsel of its own choosing and (ii) in selecting counsel to be used by the Indemnifying Party in such claim or suit. The Indemnifying Party will consult with the Indemnitee in good faith
with respect to all non-privileged aspects of the defense strategy. The Indemnitee shall cooperate with the Indemnifying Party as reasonably requested, at the Indemnifying Party’s sole cost and expense. The Indemnifying Party shall not settle
any claim or suit without the Indemnitee’s prior written consent unless such settlement is limited to the payment of cash by the Indemnifying Party and contains a full release of the Indemnitee. 
 10.4 Insurance. At all times during which any Company Product is being clinically tested with human subjects or commercially distributed or sold
by BioForm hereunder, as well as for a period of seven years thereafter, Supplier shall procure and maintain from a reputable insurer reasonably satisfactory to BioForm insurance, including product liability insurance, adequate to cover its
obligations hereunder and which is consistent with normal business practices of prudent companies similarly situated. Such insurance policy shall at all times name BioForm as an additional insured thereunder and Supplier shall provide a certificate
of insurance to BioForm evidencing such coverage. It is understood that such insurance shall not be construed to create a limit of Supplier’s liability with respect to its indemnification obligations under this Section 10. Supplier shall
provide BioForm with written evidence of such insurance (or financial information that describes the amounts available under any self-insurance facility) upon request. Supplier shall provide BioForm with written notice at least 15 calendar days
prior to the cancellation, non-renewal, or material change in such insurance. 
  

 – 20 – 

 10.5 No Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, THE PARTIES MAKE NO
REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY REPRESENTATIONS OR WARRANTIES AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 10.6 Limitation of Liability. SUPPLIER AND BIOFORM EACH AGREE THAT NO PARTY SHALL BE LIABLE TO ANY OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL,
EXEMPLARY, OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR NET PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE), OR OTHERWISE, EVEN
IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 
 11. TERM AND TERMINATION 
 11.1 Term. This Agreement shall take effect as of the Effective Date and shall remain in effect until terminated in accordance herewith (the
“Term”). 
 11.2 Termination 
 (a) BioForm may terminate this Agreement upon 90 days written notice to Supplier if Supplier fails to meet its manufacturing and supply obligations under this Agreement for a period of three consecutive months.

 (b) Supplier may terminate this Agreement upon 90 days written notice to BioForm if (i) BioForm has not designed, funded, and
conducted a Regulatory Approval Plan and diligently pursued programs with the goal of obtaining FDA approval to market and sell a Company Product in at least one applicable indication within the Field, or (ii) BioForm fails to file with the FDA
an IDE submission in at least one applicable indication within the Field by 120 days from the Effective Date, or (iii) enroll the first patient in a United States clinical trial within 180 days from the date of IDE approval. 
 (c) Either party may terminate this Agreement at any time upon 90 calendar days written notice to the other party in the event that the other party shall
have materially breached any of its obligations, representations, or warranties hereunder and shall not have cured such breach prior to the expiration of such 90 day period, which begins on the date that such written notice is received. Such notice
shall specify in reasonable detail the nature of the material breach. 
 (d) The parties may also terminate this Agreement at any time upon
mutual written agreement. 
 11.3 Exclusive Remedy. The parties agree that Supplier’s sole and exclusive remedy with respect to a
material breach by BioForm of any of the covenants set forth in Section 3.1 and Section 4.6 shall be to terminate this Agreement in accordance with Section 11.2(a), or, as applicable, 11.2(b) and receive the Development Effort Data
from BioForm if Supplier reimburses BioForm for all costs associated with the Regulatory Approval Plan, Regulatory Approvals and the physical transfer of the Development Effort Data. “Development Effort Data” means all data
obtained by BioForm in the process of implementing the Regulatory Approval Plan and obtaining regulatory authority to distribute Company Product. Supplier shall not bring, commence, continue, or prosecute any claim, legal action, or proceeding
under, in relation to, arising out of, or in connection with a breach of Section 3.1 or Section 4.6 except to cause the termination of this Agreement and obtain timely transfer of the Development Effort Data in accordance with this
Section 11.3. Notwithstanding and in addition to the rights conveyed by and limitations contained in this Section 
  

 – 21 – 

 11.3, Supplier may separately terminate its obligations under Sections 4.2, 4.3, and 4.9 at any time by so notifying
BioForm in writing if BioForm [****] of Company Product from Supplier in each 12 month period that commences at least 12 months after BioForm’s receipt of PMA approval or comparable Regulatory Approval from the FDA for at least one indication
within the Field, provided that, Supplier may only terminate its obligations pursuant to Sections 4.2, 4.3, and 4.9 after it has notified BioForm in writing of its breach and given BioForm 30 days to cure such breach. 
 11.4 Effect of Termination. Notwithstanding anything to the contrary contained herein, upon termination or expiration of this Agreement,
(a) Supplier shall continue to fill all BioForm Company Product orders made in accordance with the provisions of this Agreement prior to the date of such termination or expiration; (b) BioForm shall continue to have all rights necessary or
appropriate to sell Company Product (including Company Product delivered pursuant to post-termination orders and any Company Product ordered by BioForm prior to termination or expiration) for [****] following the date of termination or expiration,
and Supplier shall continue to comply with all of its duties and obligations hereunder necessary or appropriate to facilitate such sales by BioForm; (c) Supplier shall continue to comply with all of its duties and obligations hereunder
necessary or appropriate to permit BioForm to fulfill its obligations to deliver Company Product pursuant to tenders or sales contracts outstanding at the time of such termination or expiration until such tenders or sales contracts have expired,
including Supplier’s obligation to fill any related BioForm Company Product orders; and (d) BioForm shall take reasonable action to timely transfer to Supplier the Development Effort Data. Termination of this Agreement shall not affect
rights and obligations of either party that may have accrued prior to the effective date of termination or any obligation that by its nature or express terms survives termination. Without limiting the foregoing, the provisions of Sections 1, 5
(with respect to Company Product shipped prior to expiration or termination), 6.10, 8.4(c), 9 10, 11, and 12 shall survive any expiration or termination of this Agreement. 
 12. GENERAL PROVISIONS 
 12.1 Governing Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of New York applicable to contracts executed in and to be performed in that jurisdiction, without giving effect to its rules regarding conflicts of laws. 
 12.2 Waiver. Except as otherwise expressly set forth herein, no provision of or right under this Agreement shall be deemed to have been
waived by any act or acquiescence on the part of either party, its agents, or employees, except by an instrument in writing signed by an authorized officer of each party. No waiver by either party of any breach of this Agreement by the other party
shall be effective as to any other breach, whether of the same term or condition or any other term or condition and whether occurring before or after the date of such waiver. 
 12.3 Independent Contractors. Each party represents that it is acting on its own behalf as an independent contractor and is not acting as an
agent for or on behalf of any third party. This Agreement and the relations hereby established by and between Supplier and BioForm do not constitute a partnership, joint venture, franchise, agency, or contract of employment. 
 12.4 Assignment. Neither party may assign its rights or obligations hereunder without the prior written consent of the other, which consent
may not be unreasonably withheld, conditioned or delayed; except that either party may assign its rights and obligations hereunder to a purchaser of all or substantially all of its assets or business without the other party’s consent. It is
understood that either party may, to the extent not expressly prohibited in this Agreement, from time to time perform some or all of its obligations hereunder through one or more of its Affiliates. It is further understood and agreed that either
party may grant a security interest in its rights under the Agreement to its lender. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 – 22 – 

 12.5 Change of Control; Successors and Assigns. Notwithstanding any other provision of this
Agreement to the contrary, Supplier and BioForm will not consummate any sale, directly or indirectly, of all or substantially all of its assets or business relating to the Company Products (whether by stock sale, asset sale, merger, or otherwise)
unless the purchaser unconditionally agrees in writing, with a copy provided to the other party following closing of the transaction, that the terms of this Agreement shall be honored by the purchaser and that this Agreement shall be a binding
obligation of the purchaser. Supplier and BioForm agree to provide each other written notice of any transaction contemplated by this Section 12.5, under condition of confidentiality, including any change of control of Supplier or BioForm
(through a stock sale, asset sale, equity issuance, merger, or otherwise) prior to the closing of such transaction. This Agreement shall bind and inure to the benefit of the parties and their respective successors and permitted assigns. 

12.6 Publicity. Except as is necessary for governmental notification purposes or to comply with applicable laws and regulations or to
enforce their respective rights under this Agreement, and except as otherwise agreed to by the parties in writing, the parties shall (a) keep the material terms of this Agreement confidential and (b) agree upon the text and the exact
timing of any public announcement relating to the transactions contemplated by this Agreement. 
 12.7 Confidentiality. Each of
Supplier and BioForm acknowledge that in order to satisfy their respective obligations under this Agreement, it will be necessary for the parties to exchange certain Confidential Information. In consideration of the mutual benefits to be derived
from the exchange of Confidential Information, Supplier and BioForm agree as follows: 
 (a) Confidential Information of a disclosing party
shall be treated and safeguarded hereunder by the receiving party for a period of five years from the date of disclosure and with the same degree of care with which it treats its own Confidential Information of like character. Such receiving party
will not use Confidential Information for any purposes other than in connection with the relationship established by this Agreement. The receiving party warrants that it applies reasonable safeguards against the unauthorized disclosure and use of
Confidential Information. 
 (b) The receiving party agrees to limit access to the Confidential Information to such employees and consultants
of the receiving party who reasonably require such access in connection with the transactions contemplated by this Agreement. To the extent practicable, in the event that the receiving party is required to disclose any Confidential Information
pursuant to any law, regulation, or judicial or administrative directive, the receiving party shall promptly notify the disclosing party in order to allow the disclosing party a reasonable period of time to obtain protective or confidential
treatment of the Confidential Information before it is disclosed. 
 12.8 Further Assurances; Force Majeure. Each party covenants
and agrees that, subsequent to the execution and delivery of this Agreement and without any additional consideration, it will execute and deliver any further legal instruments and perform any acts that are or may become reasonably necessary to
effectuate the purposes of this Agreement. Any delay in the performance of any of the duties or obligations of either party shall not be considered a breach of this Agreement and the time required for performance shall be extended for a period equal
to the period of such delay; provided that such delay has been caused by or is the result of any act of God, embargo, strike, fire, flood, or other unforeseeable cause beyond the control and without the fault or negligence of the party so affected.
The party so affected shall give prompt notice to the other party of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as possible. 
 12.9 Specific Performance. Each party acknowledges that it will be impossible to measure in money the damage to the other party if a party fails
to comply with the obligations imposed by Section 12.7 of this Agreement, and that, in the event of any such failure, the other party will not have an adequate remedy 

  

 – 23 – 

 
at law or in damages. Accordingly, each party agrees that injunctive relief or other equitable remedy, in addition to remedies at law or damages, is an
appropriate remedy for any such failure and will not oppose the granting of such relief on the basis that the other party has an adequate remedy at law. Each party agrees that it will not seek, and agrees to waive any requirement for, the securing
or posting of a bond in connection with any other party’s seeking or obtaining such equitable relief. 
 12.10
Notices. Unless otherwise provided herein, any notice, report, payment, or document to be given by one party to the other shall be in writing and shall be deemed given when actually received or when delivered personally or mailed by
certified or registered mail, postage prepaid (such mailed notice to be effective on the date that is three business days after the date of mailing), or sent by reputable overnight courier (such notice sent by courier to be effective one business
day after it is deposited with such courier), and in the case of BioForm, addressed to the attention of the Chief Financial Officer, at 1875 South Grant Street, Suite 110, San Mateo, California 94402, and in the case of Supplier, addressed to the
attention of Chief Operating Officer at 1655 Roberts Blvd. NW, Kennesaw, Georgia 30144, or to such other place as any party may designate as to itself by written notice to the other party. 
 12.11 Severability. In the event any provision of this Agreement shall for any reason be held to be invalid, illegal, or unenforceable in any
respect, such invalidity, illegality, or unenforceability shall not affect any other term or provision hereof. The parties agree that they will negotiate in good faith or will permit a court to replace any provision hereof so held invalid, illegal,
or unenforceable with a valid provision that is as similar as possible in substance to the invalid, illegal, or unenforceable provision. 
 12.12 Headings. Headings of the sections and subsections of this Agreement are for reference purposes only and shall not limit or affect the meaning or construction of the terms and conditions hereof. 
 12.13 Interpretation. Words such as “herein,” “hereinafter,” “hereof,” and “hereunder” refer to this
Agreement as a whole and not merely to a section or paragraph in which such words appear, unless the context otherwise requires. The singular shall include the plural, unless the context otherwise requires. Whenever the word “include,”
“includes,” or “including” appears in this Agreement, it shall be deemed in each instance to be followed by the words “without limitation.” 
 12.14 Entire Agreement; Amendment. The terms and provisions contained in this Agreement constitute the entire understanding of the parties with respect to the transactions and matters contemplated hereby
and supersede all previous communications, representations, agreements, and understandings relating to the subject matter hereof. No agreement or understanding amending, supplementing, or extending this Agreement shall be binding upon either party
unless it is in writing and signed by the applicable party. Without limiting the foregoing, the parties anticipate that the Exhibits, Annexes, and Schedules to this Agreement may be amended or supplemented from time to time by mutual written
agreement. 
 12.15 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. 
 [The remainder of this page is intentionally left blank.]

  

 – 24 – 

 IN WITNESS WHEREOF, the parties have caused this EXCLUSIVE DEVELOPMENT, DISTRIBUTION, AND
SUPPLY AGREEMENT to be executed by their respective duly authorized officers, and have duly delivered and executed this Agreement under seal as of the date first set forth above. 
  

							
	CRYOLIFE, INC.	    	BIOFORM MEDICAL, INC.
				
	By:	 	 /s/  D. Ashley Lee
	    	By:	 	 /s/  Steven L. Basta

	Name:	 	D. Ashley Lee	    	Name:	 	Steven L. Basta
	Title:	 	EVP, COO & CFO	    	Title:	 	President & CEO

 Exhibit A 
 BSA Patents 
  

							
	[****]	 	Country	 	Title	 	Status
	[****]	 	US	 	Adhesive Composition and Method	 	Issued
				
	[****]	 	Austria	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Belgium	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Canada	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Denmark	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Europe	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Finland	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	France	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Germany	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Greece	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
		 	Ireland	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
	[****]	 	Italy	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
		 	Luxembourg	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
		 	Monaco	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
	[****]	 	Netherlands	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
	[****]	 	Norway	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
		 	Norway	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
	[****]	 	Portugal	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
		 	Spain	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
		 	Sweden	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending
				
	[****]	 	Switzerland &
Liechtenstein	 	Aldehyde-Cured Proteinaceous Adhesive	 	Issued
				
		 	United
Kingdom	 	Aldehyde-Cured Proteinaceous Adhesive	 	Pending

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 26 

 Exhibit B 
 BSA Specifications 
 BioGlue® Surgical Adhesive is a two-component surgical adhesive composed of purified bovine serum albumin and glutaraldehyde. The solutions are dispensed by a controlled delivery system, composed of a reusable delivery
device, applicator tips, and applicator tip extenders. Once dispensed, the adhesive solutions (in a pre-defined ratio) are mixed in the applicator tip where cross-linking begins. The glutaraldehyde molecules covalently bond (cross-link) the bovine
serum albumin molecules to each other and, upon application, to the tissue proteins at the repair site, creating a flexible mechanical seal independently of the body’s clotting mechanism. The delivery device-mediated application is designed to
provide reproducible mixing of the components in vitro. BioGlue begins to polymerize within 20 to 30 seconds and reaches its bonding strength within 2 minutes. BioGlue also adheres to synthetic graft materials via mechanical interlocks within
the interstices of the graft matrix. The BioGlue component has a shelf life of 3 years if stored at 25°C. 
  

			
	Test	 	 Specifications

		
	Container Integrity	 	Container is sealed with no evidence of damage
		
	Product Integrity	 	Product shows no sign of damage
		
	Seal Integrity of Inner and
Outer Pouches	 	All 4 seals complete and intact.
		
	Conformance of
non-irradiated product
code	 	Parent lot of non-irradiated material meets conformance requirements
		
	[****]	 	[****]
		
		 	[****]
		
	Count	 	Quantity of containers in batch shipped is equal to quantity irradiated and received
		
	Manufacturer and Part
Number	 	Meets that specified for pouched irradiated product code
		
	[****]	 	[****]*
		
	[****]	 	[****]*
		
	[****]	 	[****]
		
	[****]	 	[****]
		
	[****]	 	[****]
		
	Seal Strength of Outer Pouch
Seals	 	> 0.5 lbs/in.
		
	[****]	 	[****]
		
	[****]	 	[****]
		
	[****]	 	[****]

	*	The release criteria are the acceptance criteria for release of the product. The product specifications are parameters that must be met at the end of the product’s shelf-life.

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 27 

 Exhibit C 
 EC Countries 
 United Kingdom 
 France 
 Spain 
 Germany 
 Italy 
 Belgium 
 Luxembourg 
 The Netherlands 
 Switzerland 
 Austria 
 Ireland 
 Portugal 
  

 28 

 Exhibit D 
 Trademarks 
 BioGlue® and CryoLife BioGlue® 
  

 29 

 Exhibit 3.1(b) 
 Preliminary Regulatory Approval Plan 
 The contents of this exhibit are preliminary and subject to change based on i)
discussions with the FDA or applicable regulatory authorities; ii) in BioForm’s reasonable business judgment; and iii) in accordance with Section 3.1 and 3.2 of the agreement. 
 United States Regulatory Approval Plan 
 BioForm is preparing a regulatory strategy in the U.S. to secure PMA approval
to sell BioGlue for certain indications in the Field. The current strategy contemplates submitting an IDE to the U.S. FDA to conduct a pivotal clinical study in the U.S. Following execution of this agreement, BioForm plans to work closely with the
FDA to determine the appropriate endpoints and study parameters to secure such approval. Such discussions may impact the timing and study design as outlined below and BioForm will evaluate and modify, in its discretion, the regulatory approval
program accordingly. The details of the contemplated clinical study are listed below. 
 EU & Canada Regulatory Approval Plan 
 BioForm is currently evaluating regulatory strategies to secure approval for a CE Mark and the appropriate Canadian license to sell BioGlue for certain indications in the
Field. The current strategy contemplates [****] dossier in concert with CryoLife and the appropriate notified bodies [****] 
 BioForm believes that the
current data available [****], but are also determining [****]. Following the execution of the contract, BioForm will contact the respective regulatory authorities to determine the appropriate steps required to secure such approval. These steps may
include additional clinical evaluations in certain countries and depending on the outcome of such discussions, BioForm will make a determination as to the feasibility of such requests in the context of market size, opportunity and costs required to
enter these respective markets. BioForm also is contemplating certain multi-stage regulatory strategies to first secure labeling to enter the markets with the possibility of conducting additional clinical or post-market evaluations to potentially
expand the labeling. 
 BioForm will apply appropriate regulatory and financial resources utilizing both internal resources and outside consultants. BioForm
expects to work closely with CryoLife to provide references to clinical data and to facilitate conversations with the appropriate regulatory authorities. The contemplated budget has yet to be determined and will depend on the outcome of our
discussions with the regulatory authorities. 
 Potential U.S. Clinical Study Outline: 
 IDE PREPARATION OVERVIEW: 
 BioForm is planning to conduct a clinical
development program to seek at least one indication PMA approval from the FDA in the United States in the Field. BioForm believes that [****] the timelines in this plan will be adjusted accordingly. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 30 

 The IDE will include such standard provisions as a report of prior investigations of BioGlue, investigational plan,
investigator information, manufacturing information, IRB information, informed consent, among others and some of which will incorporate by reference CryoLife’s existing clinical and regulatory information. The IDE submission is currently under
development 
 PROPOSED STUDY OBJECTIVE & DESIGN: 
 The proposed pivotal clinical study will be prospectively defined to evaluate the effectiveness and safety of BioGlue in browlift surgery. The study design is currently contemplated to entail one of the following protocols: 
  

	•	 	 [****] 

  

	•	 	 [****] 

  

	•	 	 [****]. 

  

	•	 	 Other designs or comparisons to be determined 

 ENDPOINTS: 
 Effectiveness measures may be determined by the vertical lift of the brow following the procedure at various time points. As
currently contemplated (in preliminary draft form)The patients may be seen post-operatively at [****] and at [****], [****], [****], [****], and [****] post surgery in order to evaluate the healing process as well as the brow elevation. It’s
expected that efficacy may be assessed out to [****] and safety will be evaluated through [****]. 
 The level of vertical lift or suspension that is
clinically relevant shall be determined and agreed to in concert with the FDA. BioForm currently contemplates the following assessment criteria: 
  

	 	•	 	 [****]. 

  

	 	•	 	 Patients will be evaluated closely for any potential side effects associated with the surgery and BioGlue. 

 PATIENT POPULATION: 
 BioForm expects to implement standard inclusion
and exclusion criteria to screen a population of evaluable patients for this study. 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 31 

 STATISTICAL CONSIDERATIONS: 
 Standard statistical methods will be employed to determine primary and secondary efficacy and safety outcomes. Depending on the final study design, BioForm may consult with appropriate statistical authorities to both determine the
effectiveness of the surgery and accurately assess a change over time using a 95% confidence interval. 
 NUMBER OF INVESTIGATOR SITES &
PATIENTS: 
 BioForm expects to enroll up to [****] patients at up to [****] investigator sites. Standard screening and evaluation criteria may be
employed to identify the appropriate patient population. 
 POTENTIAL TIMELINE & BUDGET: 
  

					
	 Task
	  	 Potential
Date
	 	 Cost

			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	
			
	 [****]
	  	[****]	 	
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]
			
	 [****]
	  	[****]	 	[****]

  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 32 

 Exhibit 4.3 
 Other Distributors 
 Supplier has distribution agreements for its BioGlue Surgical Adhesive with [****] covering
[****] the EC Countries and [****] in Canada. While these agreements do not grant rights to distribute Company Product in the Field, the contracts themselves do not explicitly prohibit the sale of BioGlue Surgical Adhesive in the Field. Approved
applications for BioGlue Surgical Adhesive in the EC Countries and Canada are as follows: BioGlue is indicated for use as an adjunct to standard methods of surgical repair (such as sutures, staples, electrocautery, and/or patches) to bond, seal
and/or reinforce soft tissue. BioGlue may also be applied alone to seal and/or reinforce damaged parenchyma when other ligature or conventional procedures are ineffective or impractical. Indicated soft tissues are cardiac, vascular, pulmonary,
genitourinary, dural, alimentary (esophageal, gastrointestinal, and colorectal), and other abdominal (pancreatic, splenic, hepatic, and biliary). Additionally, BioGlue is used in the fixation of surgical meshes in hernia repair. For general surgical
repair procedures, BioGlue may be used to aid in the sealing, bonding, and reinforcing of parenchymal tissues. 
 Countries covered by referenced
distribution agreements are [****] 
  

	****	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 33Supplemental Employees Retirement Plan, as amended

 Exhibit 10.1 
 PENN VIRGINIA CORPORATION 
 SUPPLEMENTAL EMPLOYEE RETIREMENT PLAN 
 This is the Penn Virginia Corporation Supplemental Employee Retirement Plan (the “Plan”), as amended and restated effective January 1,
2008, which is maintained by Penn Virginia Corporation to provide supplemental retirement benefits for a select group of its management or highly compensated employees and those of its affiliates. The Plan is intended to comply with section 409A of
the Code and the regulations thereunder. 
 ARTICLE I DEFINITIONS 
 The following words and phrases as used herein have the following meanings unless a different meaning is plainly required by the context: 
 1.1. “Accounts” means Participant’s notional SERP Account, CODA Account, Deferral Contribution and Employer Stock Account maintained under the Plan. 
 1.2. “Affiliate” means any entity, trade or business that (i) is included as a member with the Sponsor in a controlled group of
corporations, within the meaning of section 414(b) of the Code; (ii) is a trade or business (whether or not incorporated) included with the Sponsor in a group of trades or business under common control, within the meaning of section 414(c) of
the Code; or (iii) is required to be aggregated with the Sponsor pursuant to section 414(m) or 414(o) of the Code and regulations thereunder. 
 1.3. “Beneficiary” means the Participant’s beneficiary as designated under the Plan on a form provided by the Committee. 
 1.4. “Change of Control” 
 (a) with respect to non-Grandfathered Amounts, the term
“Change of Control” shall have the same meaning ascribed to the term “change in control event” under section 409A of the Code, and 
 (b) with respect to Grandfathered Amounts, the term “Change of Control” means the circumstance deemed to have occurred if: 
 1.4.2. any person (a “Person”), within the meaning of Section 13(d) or 14(d) of the Exchange Act (other than (i) the Sponsor and/or its wholly-owned subsidiaries, (ii) any ESOP or other
employee benefit plan of the Sponsor, and any trustee or other fiduciary in such capacity holding securities under such a plan, (iii) any company owned, directly or indirectly, by the shareholders of the Sponsor in substantially the same
proportions as their ownership of stock of the Sponsor, or (iv) a Participant or any group of Persons of which he or she voluntarily is a part), is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of securities of the Sponsor representing 25% or more of the combined voting power of the Sponsor’s then outstanding securities; 

 1.4.3. during any consecutive two-years beginning after August 1, 1996, Directors of the Sponsor in
office at the beginning of such period plus any new Director (other than a Director designated by a person who has entered into an agreement with the Sponsor to effect a transaction within the purview of Section 1.4.2 and 1.4.4) whose election
by the Board, or whose nomination for election by the Sponsor’s shareholders, was approved by a vote of at least two-thirds of the Directors then still in office who either were Directors at the beginning of the period or whose election or
nomination for election was previously so approved, shall cease for any reason (other than retirement) to constitute at least a majority of the Board; or 
 1.4.4. the Sponsor’s shareholders or the Board shall approve (i) any consolidation or merger of the Sponsor in which the Sponsor is not the continuing or surviving corporation or pursuant to which the
Sponsor’s voting common stock would be converted into cash, securities and/or other property, other than a merger of the Sponsor in which holders of voting common stock immediately prior to the merger have the same proportionate ownership of
shares of the common stock of the surviving corporation immediately after the merger as they had in the voting common stock immediately before, (ii) any sale, lease, exchange or other transfer (in one transaction or a series of related
transactions) of all or substantially all the assets or earning power of the Sponsor, or (iii) the liquidation or dissolution of the Sponsor. 
 1.5. “CODA Account” means a separate bookkeeping account established for a Participant pursuant to Section 3.2 to which amounts equal to CODA Deferral Contributions plus any Employer contributions described in
Section 2.4.1 are credited. No further CODA Deferral Contributions shall be made after December 31, 2007. 
 1.6. “CODA
Deferral Contributions” means Deferral Contributions previously credited to a Participant’s CODA Account prior to January 1, 2008. 
 1.7. “Code” means the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder. 
 1.8. “Committee” means the Plan’s administrative committee appointed by the Sponsor. 
 1.9. “Company” means the Sponsor and any Affiliate that adopts the Plan for its Eligible Employees, with the consent of the board of directors of the Sponsor. 
 1.10. “Compensation” with respect to a Participant means base pay and bonus without taking into account the dollar limit of $150,000
(indexed for inflation) set forth in section 401(a)(17) of the Code. 
 1.11. “Contribution Year” means, as of a particular
date, the preceding calendar year. 
  

 - 2 - 

 1.12. “Date of Hire” means the first day that an employee begins employment with the
Company. 
 1.13. “Deferral Contributions” means the amount by which a Participant’s Compensation is reduced before
such Compensation becomes currently available to the Participant. 
 1.14. “Deferral Contribution Account” means Deferral
Contributions described by Section 2.2 and credited to a Participant’s Deferral Contribution Account in accordance with Section 3.1. 
 1.15. “Determination Date” means the date as of which a determination or calculation is made. 
 1.16.
“Eligible Employee” means (i) any employee of the Company who has base pay actually paid (without offset by 401(k) deferral contributions) during the Contribution Year that equals or exceeds $100,000, or (ii) in the case
of an employee of the Company who has a Date of Hire in the year of determination, an annual rate of base pay that equals or exceeds $100,000. 
 1.17. “Employer Contributions” means the amounts described in Section 2.4 that are credited to a Participant’s Employer Contribution Account. 
 1.18. “Employer Contribution Account” means a separate bookkeeping account established for a Participant pursuant to Section 3.3 to
which amounts equal to the Employer Contributions and all earnings attributable thereto are credited. 
 1.19. “Employer Stock
Account” means a separate bookkeeping account established for a Participant pursuant to Section 3.3 to which amounts equal to Employer Stock Contributions are credited. 
 1.20. “Employer Stock Contributions” means amounts described in Section 2.3 that are credited to a Participant’s Employer
Stock Account. 
 1.21. “ERISA” means the Employee Retirement Income Security Act of 1974, as amended. 
 1.22. “ESOP” means the Penn Virginia Corporation and Affiliated Companies Employee Stock Ownership Plan, intended to be an employee
stock ownership plan within the meaning of sections 409 and 4975(c) of the Code. 
 1.23. “Exchange Act” means the
Securities Exchange Act of 1934, as amended. 
  

 - 3 - 

 1.24. “Grandfathered Amounts” means the portion of a Participant’s Accounts
attributable to amounts earned and vested for purposes of section 409A of the Code as of December 31, 2004, and any earnings attributable thereto (whenever credited). 
 1.25. “Hardship” means, as determined by the Committee, and with respect to non-Grandfathered Amounts, in a manner consistent with
section 409A of the Code, a severe financial hardship to the Participant resulting from a sudden and unexpected illness or accident of the Participant or Participant’s dependent (as defined in section 152 of the Code), uninsured loss of the
Participant’s property due to casualty, or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant. 
 1.26. “Participant” means an Eligible Employee who meets the requirements of Section 2.1. 
 1.27. “Plan” means this Penn Virginia Corporation Supplemental Employee Retirement Plan, as set forth herein and as may be amended from
time to time. 
 1.28. “Plan Year” means the calendar year. 
 1.29. “SERP Account” means a separate bookkeeping account established for a Participant pursuant to Section 3.1 to which amounts
equal to SERP Deferral Contributions are credited. No further SERP Deferral Contributions shall be made after December 31, 2007. 
 1.30. “SERP Deferral Contributions” means Deferral Contributions previously credited to a Participant’s SERP Account prior to January 1, 2008. 
 1.31. “Sponsor” means Penn Virginia Corporation, a Virginia corporation. 
 1.32. “Value” means the amount of cash and the value of the shares of common stock of the Sponsor (based on the closing price of a share
of common stock of the Sponsor as of the date of liquidation) that the liquidation of the hypothetical investments of the Participant’s Account, or any portion thereof, yields as of the date of such liquidation. 
 1.33. “Year of Service” means one calendar year, measured from an employee’s Date of Hire, during which the employee is in the
employ of the Company. 
 1.34. “401(k) Plan” means the Penn Virginia Corporation and Affiliated Companies Employees’
401(k) Plan which is intended to be qualified under sections 401(a) and 401(k) of the Code. 
 ARTICLE II PARTICIPATION 
 2.1. Eligibility Requirements. Each Eligible Employee shall be eligible to participate in the Plan. An Eligible Employee shall be a Participant in
the Plan as of the first Plan Year beginning on or after he or she validly elects to participate in the Plan following the 

  

 - 4 - 

 
completion of one Year of Service. Notwithstanding the foregoing, the Committee may, in its sole and absolute discretion, waive the one Year of Service
requirement and permit a newly Eligible Employee to begin participating in the Plan within 30 days of his or her Date of Hire; provided, however, that if any portion of a Participant’s bonus is performance-based compensation for purposes of
section 409A of the Code, a deferral election with respect to the Eligible Employee’s bonus must be submitted not later than June 30 of the calendar year for which the bonus is to be earned and the deferral election will be effective only
with regard to the portion of the bonus allocable to the period following the date the Eligible Employee submits the deferral election to the Committee through the last day of the Plan Year. 
 2.2. Election to Participate. An Eligible Employee may participate in the Plan by electing to make Deferral Contributions under the Plan. An
Eligible Employee may elect to make Deferral Contributions by reducing his or her Compensation by any amount up to 100%. An Eligible Employee shall make his or her election by filing a form with the Committee that specifies the percentage or dollar
amount of Compensation to be withheld. Except where the last sentence of Section 2.1 applies, an election to have Compensation withheld pursuant to this Section 2.2 must be submitted to the Committee not later than December 31 of the
year immediately preceding the Plan Year for which the election will be effective and shall remain in effect until amended or revoked in accordance with Section 2.5; provided that if a Participant’s bonus is performance-based compensation
for purposes of section 409A of the Code, the Committee may allow the Participant to elect to defer all or portion of his bonus for a Plan Year at a time determined by the Committee, but no later than June 30 of the Plan Year for which such
bonus is to be earned. A deferral election pursuant to this Section 2.2 shall be irrevocable. 
 2.3. Employer Stock
Contributions. The Company may, if the Company so provides in its sole and absolute discretion, credit a Participant’s Employer Stock Account with an amount equal to the amount an Eligible Employee could otherwise receive under the ESOP if
he or she met all of the eligibility requirements of such ESOP. Employer Stock Contributions shall be credited in a time and manner determined by the Committee in its sole and absolute discretion. When a Participant becomes eligible to participate
in the ESOP, he or she shall no longer be eligible to receive credits for Employer Stock Contributions. 
 2.4. Discretionary Employer
Contributions. The Company may, if the Company so provides in its sole and absolute discretion, credit a Participant’s Employer Contribution Account with such amount, if any, as the Committee determines. Employer Contributions shall be
credited in a time and manner determined by the Committee in its sole and absolute discretion. 
 2.5. Reduction or Termination of
Contributions. A Participant may reduce the amount of or terminate Compensation withholding that the Company will credit to the Plan as Deferral Contributions for any Plan Year by filing a revised election form with the Committee before the
beginning of the Plan Year for which such election is to become effective. 
  

 - 5 - 

 2.6. Vesting. A Participant shall be 100% vested at all times in his or her Deferral
Contributions, CODA Employer Contributions and Employer Stock Contributions, if applicable, and any earnings credited thereon. 
 2.7.
Special 2005 Transition Rule for Bonus Compensation Earned in 2005. Notwithstanding anything in the Plan to the contrary, consistent with section 409A of the Code and the guidance issued thereunder, any Participant who made an election to
defer all or a portion of his Compensation that is a bonus earned in 2005 (payable in 2006) (the “2005 Bonus”) may cancel his election relating to his 2005 Bonus by notifying the Committee in writing in a form acceptable to the Committee.
A Participant must make such election on or before December 16, 2005. The entire amount of such 2005 Bonus shall be paid to the Participant in 2006 and includible in his income in 2006. 
 ARTICLE III INVESTMENT OF THE ACCOUNTS 
 3.1.
Establishment of the CODA Account, SERP Account and the Deferral Contribution Account. The Committee shall establish and maintain a notional account for each Participant who elects Compensation withholding under Section 2.2 and who
previously elected to make CODA Deferral Contributions and SERP Deferral Contributions. 
 3.1.1. Crediting of Amount to the Deferral
Contribution Account. An amount equal to the Compensation withheld shall be credited to a Participant’s Deferral Contribution Account not later than 60 days after the date such Compensation would otherwise have been paid to the Participant.
Hypothetical earnings, gains and losses, if any, on the balance standing to the credit of the Deferral Contribution Account shall be credited or debited to the Deferral Contribution Account as provided in Section 3.1.2. 
 3.1.2. Hypothetical Investment of the CODA Account, SERP Account and Deferral Contribution Account. The Committee may cause each
Participant’s CODA Account, SERP Account and Deferral Contribution Account to be hypothetically invested in accordance with a written investment direction provided to the Committee by the Participant. A Participant may only direct that the
Committee invest his or her CODA Account, SERP Account and Deferral Contribution Account in any investment available under the 401(k) Plan at the time such direction is given. A Participant may change his or her investment direction at such times
and on such terms and conditions as the Committee may determine, subject in all respects to the terms of the Penn Virginia Corporation Policy Regarding Special Trading Procedures. A Participant’s CODA Account, SERP Account and Deferral
Contribution Account shall be credited or debited with all hypothetical earnings, gains, losses and ordinary expenses incurred through execution of his or her investment directions. If the Participant or Committee determines not to invest the
Participant’s CODA Account, SERP Account and/or Deferral Contribution Account, the applicable Account shall be assumed to be invested in such default investment, or at the interest rate at which PNC Bank or its successor, or such other bank as
the Committee shall determine, is lending to its most credit-worthy customers less 2%; provided that in no event shall such rate exceed 8%, as the Committee determines it is sole and absolute discretion. 
  

 - 6 - 

 3.2. Establishment of the Employer Stock Account. The Committee shall establish and maintain a
notional account for each Participant who is permitted by the Committee to receive an Employer Stock Contribution under Section 2.3. 
 3.2.1. Crediting of Amount to the Employer Stock Account. The amount of contribution provided for under Section 2.3 shall be credited to a Participant’s Employer Stock Account not later than 60 days after the amount of such
contribution is determined. Hypothetical earnings, gains and losses, if any, on the balance standing to the credit of the Employer Stock Account shall be credited or debited to the Employer Stock Account as provided in Section 3.3.2.

 3.2.2. Hypothetical Investment of the Employer Stock Account. The Committee may cause each Participant’s Employer Stock
Account to be hypothetically invested in the common stock issued by the Company or shares of preferred stock issued by the Company convertible into such common stock, which shares shall constitute “qualifying employer securities” under
section 407(d)(5) of ERISA, and sections 409(l) and 4975(e)(8) of the Code. If the Participant or Committee determines not to invest the Participant’s Employer Stock Account, the Employer Stock Account shall be assumed to be invested in such
default investment, or at the interest rate at which PNC Bank or its successor, or such other bank as the Committee shall determine, is lending to its most credit-worthy customers less 2%; provided that in no event shall such rate exceed 8%, as the
Committee determines it is sole and absolute discretion. 
 3.3. Establishment of the Employer Contribution Account. The Committee
shall establish and maintain a notional account for each Participant who is permitted by the Committee to receive an Employer Contribution under Section 2.4. 
 3.3.1. Crediting of Amount to the Employer Contribution Account. The amount of contribution provided for under Section 2.4 shall be credited to a Participant’s Employer Contribution Account not later
than 60 days after the amount of such contribution is determined. Hypothetical earnings, gains and losses, if any, on the balance standing to the credit of the Employer Contribution Account shall be credited or debited to the Employer Contribution
Account as provided in Section 3.3.2. 
 3.3.2. Hypothetical Investment of the Employer Contribution Account. The Committee may
cause each Participant’s Employer Contribution Account to be hypothetically invested in accordance with a written investment direction provided to the Committee by the Participant. A Participant may only direct that the Committee invest his or
her Employer Contribution Account in any investment available under the 401(k) Plan at the time such direction is given. A Participant may change his or her investment direction at such times and on such terms and conditions as the Committee may
determine, subject in all respects to the terms of the Company’s trading policy. A Participant’s Employer Contribution Account shall be credited or debited with all hypothetical earnings, gains, losses and ordinary expenses incurred
through execution of his or her investment directions. If the Participant or Committee determines not to invest the Participant’s Employer Contribution Account, the Employer Contribution Account shall be assumed to be invested in such default
investment, or at the 

  

 - 7 - 

 
interest rate at which PNC Bank or its successor, or such other bank as the Committee shall determine, is lending to its most credit-worthy customers less
2%; provided that in no event shall such rate exceed 8%, as the Committee determines it is sole and absolute discretion. 
 3.4. Function
of Committee. Each Participant agrees that the Company and the Committee are in no way responsible for the investment results of the Participant’s notional Accounts, whether or not the Account is hypothetically invested in accordance with
the Participant’s direction. 
 ARTICLE IV DISTRIBUTION OF BENEFITS 
 4.1. Accounts. Subject to Section 4.2 and 4.4, the Value of a Participant’s Accounts shall be distributed to a Participant in a lump sum within 90 days following the earlier of (i) the
Participant’s termination of employment with the Sponsor and all of its Affiliates for any reason other than death, or (ii) a Change of Control. In addition, a Participant may receive a distribution of all or a portion of the Value of his
or her vested Accounts while employed by the Company in accordance with Section 4.3. 
 4.2. Death. Upon a Participant’s
death while employed by the Sponsor or an Affiliate, the Value of the Participant’s Accounts shall be distributed to his or her Beneficiary within 90 days following the date of the Participant’s death. 
 4.3. In-Service Distributions and Withdrawals from the Accounts. A Participant may receive a distribution of all or any portion of the Value of
his or her Accounts in accordance with this Section 4.3. 
 4.3.1. Prospective Election. A Participant may withdraw all or any
portion of the Value of the portion of his or her Accounts attributable to Grandfathered Amounts during a Plan Year, provided he or she has submitted an election form requesting the withdrawal to the Committee no later than the December 15 of
the Plan Year preceding the year of intended withdrawal (the “Election Date”). The election form shall be irrevocable as of the applicable Election Date and, to be valid, must specify (i) the percentage of the portion of
Participant’s Accounts attributable to Grandfathered Amounts he or she elects to withdraw, and (ii) the date the withdrawal shall be made, which shall in no event be earlier than March 1 of the Plan Year following the Election Date.

 A Participant may elect to receive a distribution with respect to all or any portion of the Value of the portion of his or her Deferral Contribution
Accounts attributable to non-Grandfathered Amounts in accordance with the Participant’s irrevocable in-service distribution election made at the time of the Participant’s deferral election under Section 2.2 on such terms and
conditions as the Committee may require. With respect to in-service distribution elections made with respect to the portion of a Participant’s Account attributable to non-Grandfathered Amounts in accordance with the preceding sentence, a
Participant may be permitted to file an amendment to defer further the receipt of the portion of his Account attributable to non-Grandfathered Amounts 

  

 - 8 - 

 
beyond the original in-service distribution elected by the Participant at the time of the Participant’s deferral election under Section 2.2;
provided that such amendment (a) must provide for a payout under this Section at a date at least sixty (60) months after the payout date under the applicable in-service distribution election in force immediately prior to the filing of such
an amendment, (b) must be filed with the Committee at least twelve (12) months prior to the date on which the first scheduled payment was to occur under the applicable election then in force and (c) may not take effect until at least
twelve (12) months after the date on which the election is made. Any such election change with respect to an in-service distribution election applicable to the portion of a Participant’s Account attributable non-Grandfathered Amounts shall
be made in accordance with the requirements of section 409A of the Code and the regulations thereunder and no subsequent election may result in an impermissible acceleration of payment as described in section 409A of the Code and the regulations
thereunder. 
 If a Participant has elected an in-service distribution with respect to all or a portion of the portion of the Participant’s Accounts
attributable to non-Grandfathered Amounts pursuant to this Section 4.3 and the Participant terminates employment with the Sponsor and all of its Affiliates for any reason other than death or a Change of Control occurs, in either case, prior to
the occurrence of the in-service distribution date elected by the Participant, the Participant’s Accounts shall be distributed to the Participant in accordance with Section 4.1. If a Participant has elected an in-service distribution with
respect to all or a portion of the portion of the Participant’s Accounts attributable to non-Grandfathered Amounts pursuant to this Section 4.3 and the Participant terminates employment with the Sponsor and all of its Affiliates for any
reason other than death or a Change of Control occurs, in either case, after the occurrence of the in-service distribution date elected by the Participant but before the portion of the Participant’s Accounts subject to the applicable in-service
distribution election has been fully paid to the Participant, the Participant’s Accounts shall be distributed to the Participant in accordance with the Participant’s in-service distribution election made pursuant to this Section 4.3.

 4.3.2. Hardship Withdrawal. A Participant may withdraw all or any portion of the Value of his or her Accounts during a Plan Year
by submitting a written request to the Committee, provided that the Committee determines that the Participant has incurred a Hardship and that the withdrawal is necessary to alleviate such Hardship. Subject to the requirements of section 409A of the
Code with respect to non-Grandfathered Amounts, the Committee shall deem a distribution to be necessary to alleviate a Hardship if: 
 4.3.2.1. the distribution is not in excess of the amount of the Participant’s Hardship and a reasonable estimate of taxes on such amount; and 
 4.3.2.2. the Hardship may not be relieved through reimbursement by insurance or otherwise, by liquidation of the Participant’s assets (to the extent that such liquidation would not itself cause severe financial
hardship) or by cessation of Deferral Contributions under the Plan. 
  

 - 9 - 

 4.3.3. Penalty Withdrawal of Grandfathered Amounts. A Participant who is not eligible for a
withdrawal pursuant to Section 4.3.1 or Section 4.3.2 may withdraw all or any portion of the Value of the portion of his or her Accounts attributable to Grandfathered Amounts at any time during the Plan Year by submitting an election form
to the Committee. To receive a distribution pursuant to this Section 4.3.3, the Participant shall (i) irrevocably forfeit the portion from his or her Accounts attributable to Grandfathered Amounts an amount equal to 5% of the value of the
requested distribution, and (ii) not be permitted to make Deferral Contributions to the Plan for a period of two years after the date of distribution. 
 4.3.4. Method of Withdrawals. A withdrawal pursuant to Section 4.3.1, Section 4.3.2 or Section 4.3.3 will be taken on a pro rata basis from the Accounts, unless the Participant requests a
different manner and the Committee approves such a manner in its sole and absolute discretion. 
 4.4. Delay of Payment for Specified
Employees. Notwithstanding any provision of this Plan to the contrary, if a Participant is a specified employee (within the meaning of section 409A of the Code) of the Company under section 409A at the time of his or her separation from service
(within the meaning of section 409A of the Code) with the Sponsor and all Affiliates and if payment of any benefit under the Plan is required to be delayed for a period of six months after the Participant’s separation from service pursuant to
section 409A, payment of such amount shall be delayed as required by section 409A, and the accumulated postponed amount shall be paid in a lump sum payment within 10 days after the end of the six-month period. If the Participant dies during the
postponement period prior to the payment of postponed amount, the amounts withheld on account of section 409A shall be paid to the Participant’s Beneficiary within 90 days after the date of the Participant’s death. 
 4.5. Administration of In-Service Withdrawals. The portion of a Participant’s Accounts not distributed pursuant to Section 4.3 shall
remain in the Plan, except for any amount forfeited under Section 4.3.3. Distributions shall be made as soon as administratively feasible after the Committee has reviewed and approved the request, but not later than the last day of the Plan
Year in which such request is approved. 
 4.6 Special 409A Transition Election. In accordance with procedures and in a form
established by the Committee, to the extent permitted under section 409A of the Code and the regulations issued thereunder, the Committee may permit a Participant to may make a one-time special election to change the date of distribution with
respect to all or a portion of his Account attributable to non-Grandfathered Amounts on or before December 31, 2007 on such terms as shall be determined by the Committee; provided, however, that such one-time special election may not postpone a
distribution that otherwise would be made in 2007 and may not accelerate a distribution otherwise scheduled for a later year into 2007. 
 ARTICLE V
ADMINISTRATION 
 The Plan shall be administered by the Committee; provided, however, that any member of the Committee who is a
Participant in the Plan shall be precluded from voting on any 

  

 - 10 - 

 
matter relating solely to his or her rights under the Plan. The Committee shall have the authority, responsibility and discretion to interpret and construe
the Plan and to decide all questions arising thereunder, including, without limitation, questions of eligibility for participation, eligibility for benefits and the time of the distribution thereof, and shall have the authority to deviate from the
literal terms of the Plan to the extent the Committee shall determine to be necessary or appropriate to operate the Plan in compliance with the provisions of applicable law. 
 ARTICLE VI AMENDMENT AND TERMINATION 
 6.1. Amendment. The Sponsor reserves the right, by
action of its board of directors, to amend the Plan at any time, in any manner whatsoever; provided, however, that no such amendment shall operate to reduce the accrued benefit of any Participant, or that which his or her Beneficiary would receive
in the event of his or her death. 
 6.2. Termination of the Plan. Continuance of the Plan is completely voluntary and is not assumed
as a contractual obligation of the Sponsor or any other Company. The Sponsor and each other Company shall have the right at any time, prospectively, to discontinue the Plan as to its Eligible Employees; provided, however, that such termination shall
not operate to reduce the accrued benefit of any Participant, or that which his or her Beneficiary would receive in the event of his or her death. 
 6.3. Limitation. Notwithstanding anything to the contrary contained herein, Sections 2.6, 4.1, 4.2, 6.1 and 6.2 shall become irrevocable upon a Change of Control. 
 ARTICLE VII MISCELLANEOUS 
 7.1. Claims Procedure. The Committee shall administer a claims
procedure as follows: 
 7.1.1. Initial Claim. A Participant or Beneficiary who believes himself or herself entitled to benefits
hereunder (the “Claimant”), or the Claimant’s authorized representative acting on behalf of such Claimant, must make a claim for those benefits by submitting a written notification of his or her claim of right to such benefits. Such
notification must be on the form and in accordance with the procedures established by the Committee. Except for benefits paid pursuant to Section 4.2, no benefit shall be paid under the Plan until a proper claim for benefits has been submitted.

 7.1.2. Procedure for Review. The Committee shall establish administrative processes and safeguards to ensure that all claims for
benefits are reviewed in accordance with the Plan document and that, where appropriate, Plan provisions have been applied consistently to similarly situated Claimants. Any notification to a Claimant required hereunder may be provided in writing or
by electronic media, provided that any electronic notification shall comply with the applicable standards imposed under DOL Reg. §2520.104b-1(c). 
  

 - 11 - 

 7.1.3. Claim Denial Procedure. If a claim is wholly or partially denied, the Committee shall
notify the Claimant within a reasonable period of time, but not later than 90 days after receipt of the claim, unless the Committee determines that special circumstances require an extension of time for processing the claim. If the Committee
determines that an extension of time for processing is required, written notice of the extension shall be furnished to the Claimant prior to the termination of the initial 90-day period. In no event shall such extension exceed a period of 180 days
from receipt of the claim. The extension notice shall indicate: (i) the special circumstances necessitating the extension and (ii) the date by which the Committee expects to render a benefit determination. A benefit denial notice shall be
written in a manner calculated to be understood by the Claimant and shall set forth: (i) the specific reason or reasons for the denial, (ii) the specific reference to the Plan provisions on which the denial is based, (iii) a
description of any additional material or information necessary for the Claimant to perfect the claim, with reasons therefor, and (iv) the procedure for reviewing the denial of the claim and the time limits applicable to such procedures,
including a statement of the Claimant’s right to bring a legal action under section 502(a) of ERISA following an adverse benefit determination on review. 
 7.1.4. Appeal Procedure. In the case of an adverse benefit determination, the Claimant or his or her representative shall have the opportunity to appeal to the Committee for review thereof by requesting such
review in writing to the Committee within 60 days of receipt of notification of the denial. Failure to submit a proper application for appeal within such 60 day period will cause such claim to be permanently denied. The Claimant or his or her
representative shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to the claim. A document, record or other information shall be deemed “relevant”
to a claim in accordance with DOL Reg. §2560.503-1(m)(8). The Claimant or his or her representative shall also be provided the opportunity to submit written comments, documents, records and other information relating to the claim for benefits.
The Committee shall review the appeal taking into account all comments, documents, records and other information submitted by the Claimant or his or her representative relating to the claim, without regard to whether such information was submitted
or considered in the initial benefit determination. 
 7.1.5. Decision on Appeal. The Committee shall notify a Claimant of its
decision on appeal within a reasonable period of time, but not later than 60 days after receipt of the Claimant’s request for review, unless the Committee determines that special circumstances require an extension of time for processing the
appeal. If the Committee determines that an extension of time for processing is required, written notice of the extension shall be furnished to the Claimant prior to the termination of the initial 60-day period. In no event shall such extension
exceed a period of 60 days from the end of the initial period. The extension notice shall indicate: (i) the special circumstances necessitating the extension and (ii) the date by which the Committee expects to render a benefit
determination. An adverse benefit decision on appeal shall be written in a manner calculated to be understood by the Claimant and shall set forth: (i) the specific reason or reasons for the adverse determination, (ii) the specific
reference to the Plan provisions on which the denial is based, (iii) a statement that the Claimant is entitled to receive, upon request and free 

  

 - 12 - 

 
of charge, reasonable access to and copies of all documents, records, and other information relevant to the Claimant’s claim (the relevance of a
document, record or other information will be determined in accordance with DOL Reg. §2560.503-1(m)(8)) and (iv) a statement of the Claimant’s right to bring a legal action under section 502(a) of ERISA. 
 7.1.6. Litigation. In order to operate and administer the claims procedure in a timely and efficient manner, any Claimant whose appeal with
respect to a claim for benefits has been denied, and who desires to commence a legal action with respect to such claim, must commence such action in a court of competent jurisdiction within 90 days of receipt of notification of such denial.
Failure to file such action by the prescribed time will forever bar the commencement of such action. 
 7.2. Title to Assets. Title to
and beneficial ownership of any assets, whether cash or investments, that the Company may set aside or earmark to meet its obligations hereunder, shall at all times remain in the Company; provided that the trustee shall hold legal title to any
assets placed in a trust. No Participant or Beneficiary shall under any circumstances acquire any property interest in any specific assets set aside in trust by the Company. Any funds that may be invested under the provisions of the Plan shall
continue for all purposes to be a part of the general funds of the Company and no person other than the Company shall by virtue of the provisions of the Plan have any interest in such funds. To the extent that any person acquires a right to receive
payments under the Plan, such right shall be no greater than the right of any other unsecured general creditor of the Company. 
 7.3.
Non-alienation. The right of a Participant or any other person to the payment of any benefit hereunder shall not be assigned, transferred, pledged or encumbered. 
 7.4. Incapacity. If the Committee shall find that any person to whom any payment is due under the Plan is unable to care for his or her affairs because of illness or accident, or is a minor, any payment due
(unless a prior claim therefor shall have been made by a duly appointed guardian or other legal representative) may be paid to the person deemed by the Committee to have responsibility for such person otherwise entitled to payment, in such manner
and proportions as the Committee may determine. Any such payment shall be a complete discharge, to the extent of the payment, of the liabilities of the Plan, the Company, the Committee, and the trustee. 
 7.5. No Employment Contract. Nothing contained herein shall be construed as conferring upon a Participant the right to continue in the employ of
the Company in any capacity. 
 7.6. Succession. The Plan and any related agreements shall be binding upon and inure to the benefit of
the Company, and its successors and assigns, and the Participants and their heirs, executors, administrators and legal representatives. 
 7.7. Number. For purposes of the Plan, the singular shall include the plural, and vice versa. 
  

 - 13 - 

 7.8. Governing Law. The Plan shall be construed in accordance with and governed by the laws of the
Commonwealth of Virginia, except to the extent superseded by federal law. 
 7.9. Section 409A. The Plan is intended to comply
with the applicable requirements of section 409A of the Code and its corresponding regulations and related guidance, and shall be administered in accordance with section 409A of the Code to the extent section 409A of the Code applies to the Plan.
All payments to be made upon a termination of employment or service under the Plan may only be made upon a “separation from service” under section 409A of the Code. Notwithstanding anything in the Plan to the contrary, deferral elections
and distributions from the Plan may only be made in a manner and upon an event permitted by section 409A of the Code. Except with respect to elections made in accordance with Article IV, in no event shall a Participant, directly or indirectly,
designate the calendar year of payment. 
 IN WITNESS WHEREOF, Penn Virginia
Corporation has caused its duly authorized officers to execute this amendment and restatement of the Plan as of the 24th day of October, 2007.

  

									
		 		 	PENN VIRGINIA CORPORATION
					
	 Attest:
	 	 /s/ Jean M. Whitehead
	 		 	By:	 	 /s/ Nancy M. Snyder

  

 - 14 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]